[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10478
1. Watt CD, Bagg A: Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn; 2010 Nov;10(8):993-1012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of acute myeloid leukemia.
  • The diagnosis and classification of acute myeloid leukemia is multifaceted, requiring the integration of a variety of laboratory findings, with genetic approaches now firmly established as a central component.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Molecular Diagnostic Techniques

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21080817.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


2. Rowe D, Strain L, Lowe C, Jones G: A case of acute myeloid leukemia with inv(16)(p13q22) reveals a novel MYH11 breakpoint and a new CBF beta-MYH11 transcript variant. Haematologica; 2007 Oct;92(10):1433-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of acute myeloid leukemia with inv(16)(p13q22) reveals a novel MYH11 breakpoint and a new CBF beta-MYH11 transcript variant.
  • We present a case of acute myeloid leukemia (AML) with a cytogenetically typical inv(16)(p13q22), M4 morphology and eosinophilia.
  • However, studies revealed a CBF beta-MYH11 fusion transcript which did not correspond to any of the 10 known variants.
  • [MeSH-major] Chromosomes, Human, Pair 16 / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024381.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


3. Zhang Y, Liu T, Yan P, Huang T, Dewille J: Identification and characterization of CCAAT/Enhancer Binding proteindelta (C/EBPdelta) target genes in G0 growth arrested mammary epithelial cells. BMC Mol Biol; 2008 Oct 01;9:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C/EBPdelta is highly expressed in G0 growth arrested mammary epithelial cells (MECs) and "loss of function" alterations in C/EBPdelta have been associated with impaired contact inhibition, increased genomic instability and increased cell migration.
  • Reduced C/EBPdelta expression has also been reported in breast cancer and acute myeloid leukemia (AML).
  • RESULTS: ChIP-chip assays identified approximately 100 C/EBPdelta target gene loci which were classified by gene ontology (GO) into cell adhesion, cell cycle regulation, apoptosis, signal transduction, intermediary metabolism, gene transcription, DNA repair and solute transport categories.
  • The identification and validation of C/EBPdelta target genes provides new insights into the mechanistic role of C/EBPdelta in mammary epithelial cell biology and sheds new light on the potential impact of "loss of function" alterations in C/EBPdelta in tumorigenesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 1998 Feb;174(2):232-9 [9428809.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1657-69 [17902160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10908-13 [9724803.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 29;266(3):677-83 [10603305.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):57-63 [10634518.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):29123-31 [10867011.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7084-93 [11156415.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5697-702 [11479200.001]
  • [Cites] Mech Dev. 2001 Dec;109(2):281-93 [11731240.001]
  • [Cites] Leuk Res. 2002 May;26(5):451-7 [11916518.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):561-75 [12006103.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6321-35 [12192032.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):601-10 [12479220.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Mar;228(3):278-85 [12626772.001]
  • [Cites] Mol Cell Probes. 2003 Feb;17(1):11-4 [12628588.001]
  • [Cites] J Biol Chem. 2003 Mar 21;278(12):10465-76 [12533540.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):362-75 [12651909.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):310-8 [12791297.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):533-42 [12875973.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1549-57 [14716301.001]
  • [Cites] Cell Mol Life Sci. 2004 Sep;61(17):2189-99 [15338051.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Sep;229(8):705-21 [15337825.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6410-5 [15374948.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1538-52 [1840554.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Biochim Biophys Acta. 1993 Nov 3;1170(3):291-5 [8105893.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):4324-32 [8196668.001]
  • [Cites] Mech Dev. 1996 May;56(1-2):197-207 [8798158.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6291-6 [9045647.001]
  • [Cites] Dev Dyn. 1998 Oct;213(2):159-69 [9786416.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29279-82 [9792624.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16582-9 [10347224.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):696-701 [10471388.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R75-91 [14979920.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 31;230(1-2):59-68 [15664452.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):830-43 [15389879.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):844-56 [15389878.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1589-97 [15674331.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4762-8 [15930295.001]
  • [Cites] J Cell Sci. 2005 Jun 15;118(Pt 12):2545-55 [15944395.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):662-87 [15798098.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6667-75 [16007164.001]
  • [Cites] J Cell Sci. 2005 Dec 1;118(Pt 23):5453-63 [16278295.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11429-36 [16357151.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):927-33 [16301319.001]
  • [Cites] Mol Endocrinol. 2006 Mar;20(3):675-85 [16293640.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(2):161-70 [16322893.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3160-9 [16407826.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6899-902 [16849531.001]
  • [Cites] Blood. 2007 May 1;109(9):3895-905 [17234736.001]
  • [Cites] J Cell Biol. 2007 Jun 18;177(6):1037-49 [17562792.001]
  • [Cites] Biochem J. 2007 Jul 15;405(2):341-9 [17373909.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2108-17 [9528783.001]
  • (PMID = 18828910.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R29 CA057607; United States / NCI NIH HHS / CA / CA57607-14; United States / NCI NIH HHS / CA / R01 CA057607; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / P30 CA016058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 142662-43-9 / CCAAT-Enhancer-Binding Protein-delta
  • [Other-IDs] NLM/ PMC2576343
  •  go-up   go-down


Advertisement
4. Wang L, Harshman SW, Liu S, Ren C, Xu H, Sallans L, Grever M, Byrd JC, Marcucci G, Freitas MA: Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia. Proteomics; 2010 Dec;10(23):4281-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.
  • As many promising targeted therapies affect kinase activity of specific enzymes involved in cancer transformation, H1 phosphorylation can serve as potential pharmacodynamic marker for drug activity within the cell.
  • In this study we utilized a phosphoproteomic workflow to characterize histone H1 phosphorylation changes associated with two targeted therapies in the Kasumi-1 acute myeloid leukemia cell line.
  • In contrast, independent treatments with a nucleotide analog, proteosome inhibitor and histone deacetylase inhibitor did not exhibit decreased H1.5 phosphorylation.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Sci. 1994 Apr;3(4):575-87 [8003976.001]
  • [Cites] Anal Biochem. 1994 May 15;219(1):9-20 [8059960.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Aug 15;202(3):1657-63 [8060353.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11510-5 [8876166.001]
  • [Cites] Protein Sci. 1997 Nov;6(11):2436-45 [9385646.001]
  • [Cites] Anal Chem. 1998 May 15;70(10):2050-9 [9608844.001]
  • [Cites] Mol Cell Biochem. 1998 Aug;185(1-2):33-8 [9746209.001]
  • [Cites] J Am Soc Mass Spectrom. 1998 Nov;9(11):1175-88 [9794085.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1219-27 [15595731.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):667-72 [15647351.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1530-6 [15539946.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1768-76 [15514006.001]
  • [Cites] Methods Enzymol. 2004;375:278-97 [14870674.001]
  • [Cites] Anal Chem. 2004 Mar 1;76(5):1532-6 [14987115.001]
  • [Cites] Methods. 2004 May;33(1):53-8 [15039087.001]
  • [Cites] Trends Mol Med. 2004 Feb;10(2):47-51 [15106614.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):42-3 [14726680.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3645-52 [15150124.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1466-7 [14976030.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3935-43 [15253627.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5 [15302935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13417-22 [15347803.001]
  • [Cites] Cell. 1977 Sep;12(1):101-7 [561660.001]
  • [Cites] J Cell Biol. 1979 Nov;83(2 Pt 1):403-27 [387806.001]
  • [Cites] Nature. 1980 Mar 13;284(5752):181-3 [7360244.001]
  • [Cites] Int J Biochem. 1980;11(6):577-85 [7380083.001]
  • [Cites] Biochemistry. 1981 Jul 21;20(15):4414-9 [7284331.001]
  • [Cites] Pediatr Res. 2005 Mar;57(3):430-7 [15659698.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1640-9 [18314942.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2368-79 [18416567.001]
  • [Cites] Electrophoresis. 2008 Jul;29(14):3047-54 [18655040.001]
  • [Cites] J Proteome Res. 2008 Oct;7(10):4326-35 [18754630.001]
  • [Cites] Acta Haematol. 2008;120(1):19-30 [18716397.001]
  • [Cites] Proteomics. 2009 Apr;9(7):1763-70 [19288523.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1019-28 [19194470.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):498-506 [19811823.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):179-84 [10618391.001]
  • [Cites] Invest New Drugs. 1999;17(3):313-20 [10665481.001]
  • [Cites] J Am Soc Mass Spectrom. 2000 Apr;11(4):273-82 [10757163.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30478-86 [10874037.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(3):191-202 [11180550.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):379-82 [11283599.001]
  • [Cites] Anal Chem. 2001 Jun 1;73(11):2578-86 [11403303.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(16):1481-8 [11507762.001]
  • [Cites] Proteomics. 2001 Feb;1(2):207-22 [11680868.001]
  • [Cites] Trends Biotechnol. 2002 Jun;20(6):261-8 [12007495.001]
  • [Cites] Mol Cancer Ther. 2003 Jan;2(1):73-81 [12533675.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):517-27 [12648512.001]
  • [Cites] Nat Biotechnol. 2003 Sep;21(9):1047-54 [12923550.001]
  • [Cites] Anal Chem. 2003 Jul 1;75(13):3232-43 [12964774.001]
  • [Cites] Cell. 2003 Sep 19;114(6):655-6 [14505563.001]
  • [Cites] Cell. 2003 Sep 19;114(6):673-88 [14505568.001]
  • [Cites] FEBS Lett. 1986 Aug 11;204(1):61-6 [3091399.001]
  • [Cites] J Cell Biol. 1990 Nov;111(5 Pt 1):1753-62 [2172257.001]
  • [Cites] Mol Cell Proteomics. 2005 Mar;4(3):310-27 [15665377.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):424-34 [15822919.001]
  • [Cites] Blood. 2005 Jul 1;106(1):318-27 [15784732.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):873-86 [15858219.001]
  • [Cites] Hematology. 2005 Jun;10(3):225-35 [16019471.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Oct;16(10):1641-53 [16099169.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):219-22 [16197453.001]
  • [Cites] Biochemistry. 2005 Nov 22;44(46):15287-95 [16285732.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Dec;16(12):2027-38 [16253516.001]
  • [Cites] Mol Pharmacol. 2006 Jan;69(1):288-98 [16219908.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):584-90 [16428504.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6573-80 [16377619.001]
  • [Cites] Anal Chem. 2006 Mar 15;78(6):1743-9 [16536406.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(9):1400-4 [16572382.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):728-31 [16620576.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):949-58 [16478717.001]
  • [Cites] Mol Cell Proteomics. 2006 Sep;5(9):1593-609 [16835217.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):72-87 [17043054.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):692-702 [17308065.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1139-44 [17330947.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(9):1546-54 [17415803.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jun;321(3):953-60 [17389244.001]
  • [Cites] BMC Bioinformatics. 2007;8:133 [17448237.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5418-24 [17545623.001]
  • [Cites] J Chromatogr A. 2007 Sep 21;1165(1-2):128-35 [17714720.001]
  • [Cites] Anal Biochem. 2007 Nov 1;370(1):77-86 [17659250.001]
  • [Cites] Haematologica. 2008 Jan;93(1):57-66 [18166786.001]
  • [Cites] Haematologica. 2008 Jan;93(1):75-82 [18166788.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):138-44 [18072732.001]
  • [Cites] Exp Hematol. 2008 Feb;36(2):149-57 [18206726.001]
  • [Cites] PLoS One. 2008;3(2):e1553 [18253500.001]
  • [Cites] Proteomics. 2008 Mar;8(5):994-9 [18324724.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1488-96 [17879944.001]
  • [Cites] Trends Biochem Sci. 1992 Mar;17(3):93-8 [1412698.001]
  • [Cites] J Biol Chem. 1994 Apr 1;269(13):9568-73 [8144543.001]
  • (PMID = 21110323.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR023647; United States / NCI NIH HHS / CA / CA101956; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCRR NIH HHS / RR / S10 RR023647; United States / NCI NIH HHS / CA / R01 CA107106-01; United States / NCRR NIH HHS / RR / S10 RR023647-01; United States / NCI NIH HHS / CA / CA107106-01; United States / NCI NIH HHS / CA / R01 CA107106; United States / NCI NIH HHS / CA / CA107106; United States / NCRR NIH HHS / RR / RR023647-01; United States / NCI NIH HHS / CA / R56 CA107106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Biomarkers, Pharmacological; 0 / Caseins; 0 / Flavonoids; 0 / HSP90 Heat-Shock Proteins; 0 / Histones; 0 / Lactams, Macrocyclic; 0 / Phosphopeptides; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 45AD6X575G / alvocidib; 4GY0AVT3L4 / tanespimycin
  • [Other-IDs] NLM/ NIHMS262344; NLM/ PMC3021470
  •  go-up   go-down


5. Arana-Yi C, Block AW, Sait SN, Ford LA, Barcos M, Baer MR: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res; 2008 Jul;32(7):1043-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
  • Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/t-AML) have been reported only rarely following treatment of AML.
  • We report five patients treated for de novo AML who developed t-MDS/t-AML, all with chromosome 7 abnormalities, including -7, del(7)(q22q36) and del(7)(p11.22p22).
  • These cases further document t-MDS/t-AML as a complication of therapy for AML.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytarabine / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / drug therapy


6. Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H: Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci; 2010 Mar;101(3):594-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
  • WT1 (Wilms' tumor gene 1) protein is a potent pan-tumor-associated antigen (TAA) and WT1-specific cytotoxic T lymphocytes (WT1 tetramer(+) CD8(+) T cells) are spontaneously induced in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • We conducted a single-cell level comparative analysis of T-cell receptor beta-chain variable region (TCR-BV) gene families of a total of 1242 spontaneously induced WT1 tetramer(+) CD8(+) T cells in HLA-A*2402(+) patients with AML or MDS and those in healthy donors (HDs).
  • This is the first report of direct usage analysis of TCR-BV gene families of individual TAA-specific CD8(+) T cells at single-cell level.
  • Usage analysis using single-cell RT-PCR of TCR-BV gene families of individual FACS-sorted WT1 tetramer(+) CD8(+) T cells showed for the first time (i) that BVs 5, 6, 20, and 27 were commonly biased in both HDs and patients;.
  • (iii) that BV19 was commonly biased in the patients; and (iv) that BVs 7 and 28, BVs 9 and 15, and BVs 12 and 29 were specifically biased in HDs, AML, and MDS patients, respectively.
  • However, statistical analysis of similarity among HD, AML, and MDS of individual usage frequencies of 24 kinds of TCR-BV gene families indicated that the usage frequencies of TCR-BV gene families in AML and MDS patients reflect those in HDs.
  • These findings represent a novel insight for a better understanding of WT1-specific immune response.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Genes, T-Cell Receptor beta. Leukemia, Myeloid, Acute / immunology. Myelodysplastic Syndromes / immunology. WT1 Proteins / immunology


7. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J: Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res; 2010 Apr;34(4):535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
  • We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin.
  • Here we investigate the sensitivity of acute myelogenous leukemia (AML) cell lines to protein synthesis inhibition in combination with the standard cytotoxic agents daunorubicin, etoposide, and cytarabine.
  • Silvestrol shows synergy with standard-of-care agents in AML cell lines and synergizes with ABT-737, a small molecule inhibitor of Bcl-X(L) and Bcl-2.
  • The in vitro synergy between silvestrol and the cytotoxic drugs used in AML therapy provides a basis for in vivo evaluation of these combinations.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Annu Rev Biochem. 1999;68:913-63 [10872469.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1446-54 [19322212.001]
  • [Cites] Hematology. 2002 Feb;7(1):21-31 [12171774.001]
  • [Cites] Blood. 2003 Jan 15;101(2):425-32 [12393493.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4202-9 [15304385.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):723-31 [16546987.001]
  • [Cites] Leuk Res. 2006 Nov;30(11):1447-51 [16704876.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Science. 2006 Oct 20;314(5798):467-71 [17053147.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):375-88 [17097560.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Cell. 2007 Jan 26;128(2):257-67 [17254965.001]
  • [Cites] PLoS One. 2007;2(2):e242 [17311107.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3509-12 [17179228.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1025-8 [17426258.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2638-48 [17786246.001]
  • [Cites] Oncologist. 2007;12 Suppl 2:14-21 [18039635.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3232-7 [18055695.001]
  • [Cites] Curr Cancer Drug Targets. 2008 May;8(3):207-22 [18473734.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):705-12 [18594212.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2651-60 [18551192.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1728-36 [18548093.001]
  • [Cites] Cancer Lett. 2009 Feb 8;274(1):16-24 [18829157.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):1003-16 [19176198.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):1017-25 [19176199.001]
  • [Cites] PLoS One. 2009;4(4):e5223 [19401772.001]
  • [Cites] Blood. 2009 May 7;113(19):4656-66 [19190247.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1438-45 [11350915.001]
  • (PMID = 19726085.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073855; Canada / Canadian Institutes of Health Research / / MOP-79385
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABT-737; 0 / Biphenyl Compounds; 0 / Cytotoxins; 0 / Nitrophenols; 0 / Peptide Initiation Factors; 0 / Piperazines; 0 / Protein Synthesis Inhibitors; 0 / Sulfonamides; 0 / Triterpenes; 0 / silvestrol; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS616104; NLM/ PMC4117193
  •  go-up   go-down


8. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP: Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem; 2010 May 14;285(20):15010-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of oxidative stress in the relapse of acute myeloid leukemia.
  • The aims of the present study were to determine the level of oxidative stress and the salient factors leading to the relapse of acute myeloid leukemia (AML).
  • Oxidative stress-related parameters and the expressions of specific genes were monitored in 102 cases of AML during a pretreatment period from a primary status to a relapse status.
  • Linear regression showed that a low T-AOC and up-regulated TRX expression were the independent factors correlated with relapse.
  • A strong association between oxidative stress and the incidence of disease relapse was observed, which has potential prognosis implications.
  • These results indicate that oxidative stress is a crucial feature of AML and probably affects the development and relapse of AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Oxidative Stress

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2009 Jul;37(7):2155-9 [19487947.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1379-86 [16923572.001]
  • [Cites] Leuk Res. 2007 Mar;31(3):387-93 [16949154.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):792-801 [17234791.001]
  • [Cites] J Pharm Pharmacol. 2007 Mar;59(3):409-17 [17331345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93 [17640917.001]
  • [Cites] Immunol Lett. 2007 Aug 15;111(2):69-75 [17644189.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2616-20 [17564752.001]
  • [Cites] Diabetes. 2008 Apr;57(4):879-88 [18003754.001]
  • [Cites] Clin Biochem. 2008 May;41(7-8):511-8 [18313403.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1221-7 [18313749.001]
  • [Cites] Acta Physiol Hung. 2008 Jun;95(2):209-18 [18642760.001]
  • [Cites] Gen Physiol Biophys. 2008 Jun;27(2):71-84 [18645221.001]
  • [Cites] Antioxid Redox Signal. 2008 Oct;10(10):1813-48 [18593226.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1685-91 [18580952.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):613-5 [18623225.001]
  • [Cites] Biomed Environ Sci. 2008 Aug;21(4):286-9 [18837290.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 [18684987.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1969-72 [18401418.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):741-6 [18680148.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 15;45(6):875-84 [18638547.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1894-8 [19050070.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):319-23 [18758816.001]
  • [Cites] Mol Nutr Food Res. 2009 Jan;53(1):87-103 [18979503.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):490-4 [18639339.001]
  • [Cites] Zhongguo Dang Dai Er Ke Za Zhi. 2009 Feb;11(2):88-92 [19222940.001]
  • [Cites] Circ Res. 2009 Mar 27;104(6):750-7 [19179658.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39 [19412858.001]
  • [Cites] Cell Death Differ. 2009 Jun;16(6):847-57 [19247368.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1367-71 [19327827.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1297 [19560202.001]
  • [Cites] Nephron Clin Pract. 2009;112(4):c255-61 [19546585.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Sep;12(8):1089-96 [19272208.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):446-52 [18979530.001]
  • [Cites] Cancer Biol Ther. 2009 Jul;8(14):1402-8 [19597340.001]
  • [Cites] Yonsei Med J. 2009 Oct 31;50(5):677-82 [19881972.001]
  • [Cites] J Mol Endocrinol. 2009 Dec;43(6):251-61 [19620238.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):461-8 [10781678.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):41-5 [15158439.001]
  • [Cites] J Clin Lab Anal. 1992;6(1):47-53 [1542083.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] Clin Chem Lab Med. 2005;43(3):294-7 [15843234.001]
  • [Cites] Drug Resist Updat. 2005 Oct;8(5):322-30 [16230045.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Perit Dial Int. 2006 Mar-Apr;26(2):207-12 [16623427.001]
  • [Cites] Toxicology. 2007 Jan 5;229(1-2):1-10 [17118505.001]
  • (PMID = 20233720.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.4.3.4 / Monoamine Oxidase; EC 3.5.4.4 / Adenosine Deaminase
  • [Other-IDs] NLM/ PMC2865279
  •  go-up   go-down


9. Stevens JM, Macdougall F, Jenner M, Oakervee H, Cavenagh J, Lister AT: Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre. Br J Haematol; 2009 Apr;145(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.
  • This study assessed the recruitment to an acute myeloid leukaemia (AML) trial (AML15) in a single centre, evaluated whether outcome was influenced by trial entry and whether the trial population could be considered representative of all AML patients by retrospective comparison of patient characteristics, trial entry and outcome for 81 consecutive patients (<60 years).
  • All patients were considered for trial entry, however the trial was not offered to 12 (15%) patients.
  • Thus the overall survival estimates generated from large phase III trials may indicate that the outcome for patients with AML is better than the outcome experienced in the 'real' world.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Leukemia, Myeloid, Acute / drug therapy. Patient Selection. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210510.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Schoonmaker JP, Trenkle AH, Beitz DC: Effect of feeding wet distillers grains on performance, marbling deposition, and fatty acid content of beef from steers fed low- or high-forage diets. J Anim Sci; 2010 Nov;88(11):3657-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steers fed a low-forage diet gained BW faster (P < 0.001) than did steers fed a high-forage diet; the amount of WDG fed did not affect (P = 0.25) daily BW gain.
  • Longissimus muscle area (P = 0.08) and yield grade (P < 0.01) were greater for steers fed low-forage diets compared with steers fed high-forage diets.
  • Longissimus muscle area (P = 0.02) and yield grade (P = 0.03) increased as WDG concentration increased.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601523.001).
  • [ISSN] 1525-3163
  • [Journal-full-title] Journal of animal science
  • [ISO-abbreviation] J. Anim. Sci.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids
  •  go-up   go-down


11. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O: In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res; 2005 Feb;29(2):185-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8.
  • Interactions between native human acute myelogenous leukemia (AML) blasts and nonleukemic cells in the bone marrow microenvironment seem important both for disease development chemosensitivity.
  • Native human AML blasts from consecutive patients were cultured with normal human bone marrow stromal cells and two fibroblast lines (HFL1 and Hs27) separated by a semipermeable membrane.
  • This bidirectional crosstalk via the cytokine network between AML blasts and fibroblasts caused (i) increased proliferation, (ii) mediated antiapoptotic signalling and (iii) increased local levels of proangiogenic IL8.
  • [MeSH-major] Cell Communication. Cytokines / physiology. Fibroblasts / physiology. Interleukin-8 / biosynthesis. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / physiology. Cell Line, Tumor. Cell Proliferation. Coculture Techniques. Disease Progression. Female. Humans. Male. Middle Aged. Signal Transduction. Stromal Cells / physiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607368.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-8
  •  go-up   go-down


12. Martins C, Lacerda JF, Lourenço F, Carmo JA, Lacerda JM: Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Acta Med Port; 2005 Sep-Oct;18(5):329-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
  • We report our results of autologous stem cell transplantation (SCT) in patients with AML during the last 13 years.
  • Between August 1990 and December 2003, 42 patients with acute myeloid leukemia (AML) received an autologous SCT.
  • Patients were classified as standard risk if first complete remission (CR) was induced after one or two chemotherapy regimens and the white blood cell count at presentation was below 50,000/mL (n=12), while patients requiring more than two induction regimens to attain first CR and with CR2 ou more advanced disease and/or had a higher white blood cell count at presentation were defined as high risk (n=30).
  • The median patient age was 24 years (range, 2-56 years), and the median time interval from diagnosis to autologous SCT was 9 months (range 3-87 months).
  • The conditioning regimen for SCT consisted of busulfan (BU) 16 mg/kg and melfalan (MEL) 180 mg/m2 (BUMEL) in 17 (40%) patients and busulfan 16 mg/kg and VP-16 60 mg/kg (BUVP16) in 22 (52%) patients.
  • Three patients received a different conditioning regimen with BCNU 300 mg/m2, VP16 2 g/m2 and melphalan 160 mg/m2 (BEM).
  • Patients with FAB M3 subtype also had a superior OS than the other FAB subtypes (100% vs 44%, p=0.05).
  • In fact, the patients with standard risk had a superior OS and DFS than those with high risk disease (67% vs 23%, p=0.0004; and 50% vs 27%, p=0.01, respectively).
  • When patients with FAB M3 disease were excluded from the analysis, the group with standard risk continue to have a superior OS and DFS (67% vs 13%, p=0.008; and 50% vs 14%, p=0.02, respectively).
  • We conclude that autologous SCT is an effective treatment in AML with the possibility of long survivorship, particularly in patients with standard risk disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome


13. Neumann F, Gattermann N, Barthelmes HU, Haas R, Germing U: Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Leuk Res; 2009 Feb;33(2):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
  • The risk of AML evolution was higher in patients with B2M> or =2mg/dl.
  • Using multivariate analysis we found the B2M level at the time of diagnosis to be an independent prognostic parameter for survival and for the risk of developing AML in high-risk MDS patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / diagnosis. beta 2-Microglobulin / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Young Adult


14. Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M: Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol; 2008 Sep 10;26(26):4326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.
  • PURPOSE: Identify prognostic factors that influence outcome after unrelated donor bone marrow transplantation in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS: Included are 268 patients (age <or= 18 years) with AML in second complete remission (n = 142), relapse (n = 90), or primary induction failure (n = 36) at transplantation.
  • RESULTS: In this analysis, the only risk factor that predicted leukemia recurrence and overall and leukemia-free survival was disease status at transplantation.
  • The 5-year probabilities of leukemia-free survival were 45%, 20%, and 12% for patients who underwent transplantation at second complete remission, relapse, and primary induction failure, respectively.
  • As expected, risk of acute but not chronic graft-versus-host disease (GVHD) was lower with T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associated with higher risks of leukemia recurrence.
  • We observed similar risks of leukemia relapse in patients with and without acute and chronic GVHD.
  • CONCLUSION: Children who underwent transplantation in remission had a superior outcome compared with children who underwent transplantation during relapse or persistent disease.
  • Nevertheless, 20% of children who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effective therapy in a significant proportion of children with recurrent or primary refractory AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1611-9 [12393725.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2940-7 [12885813.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1534-8 [9766496.001]
  • [Cites] Leukemia. 1999 Jan;13(1):25-31 [10049056.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Lancet. 2005 Aug 27-Sep 2;366(9487):733-41 [16125590.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9172-8 [16361619.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):157-63 [17133407.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • (PMID = 18779619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2653120
  •  go-up   go-down


15. Rodríguez Pérez A, López Carrizosa MC, Villalón Blanco L, Samper Ots PM, Ortiz Cruz E: Granulocytic sarcoma of the right humerus in a non-leukaemia patient. Clin Transl Oncol; 2008 Nov;10(11):758-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the right humerus in a non-leukaemia patient.
  • Granulocytic sarcoma (GS), an uncommon solid extramedullary tumour, should be considered even in the absence of leukaemia, as delay in diagnosis and treatment worsens the prognosis.
  • We present a GS (single humeral bone lesion) in a non-leukaemia patient, treated with intensive AML (Acute Myeloid Leukaemia) chemotherapy and sequential radiotherapy, in complete response 26 months after diagnosis, confirmed by histopathology and without leukaemia progression.
  • [MeSH-major] Bone Neoplasms / diagnosis. Humerus / pathology. Sarcoma, Myeloid / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Med Clin (Barc). 1995 Mar 18;104(10):377-80 [7707732.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2527-41 [17169797.001]
  • [Cites] Strahlenther Onkol. 2003 Mar;179(3):187-90 [12627262.001]
  • [Cites] Leuk Res. 2004 Nov;28(11):1165-9 [15380340.001]
  • [Cites] Orthopedics. 1999 Aug;22(8):773-5 [10465491.001]
  • (PMID = 19015073.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


16. Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr GW, Jücker M: Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D. Gene Ther; 2009 Apr;16(4):570-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
  • Acute myeloid leukemia (AML) is a malignant disease characterized by deregulated proliferation of immature myeloid cells.
  • Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently detected in approximately 50-70% of AML patients.
  • After lentiviral-mediated gene transfer of INPP5D into CD34(+) cells derived from AML patients (n=12) the granulocyte macrophage-colony stimulating factor (GM-CSF)-dependent proliferation was reduced in all samples analyzed (average 86%; range 72-93%).
  • In addition, SHIP1 reduced the autonomous proliferation of CD34(+) cells from a patient with a secondary AML who had a very high peripheral blast count (300 x 10(9) l(-1)).
  • These data show that SHIP1 can effectively block GM-CSF-dependent and autonomous proliferation of AML cells.
  • [MeSH-major] Antigens, CD34 / blood. Leukemia, Myeloid, Acute / pathology. Phosphoric Monoester Hydrolases / genetics
  • [MeSH-minor] Cell Proliferation / drug effects. Gene Transfer Techniques. Genetic Vectors. Humans. Lentivirus / genetics. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Ribonucleosides / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148132.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ribonucleosides; 2421HMY9N6 / triciribine; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.56 / inositol-polyphosphate 5-phosphatase
  •  go-up   go-down


17. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev; 2008 Feb;34(1):49-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
  • Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetyl-calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic.
  • GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy.
  • GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation.
  • GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual disease.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942233.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  • [Number-of-references] 77
  •  go-up   go-down


18. Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, Dheda K: Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. PLoS One; 2010 Dec 22;5(12):e15664
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting.
  • BACKGROUND/OBJECTIVE: The diagnosis of tuberculous meningitis (TBM) in resource poor TB endemic environments is challenging.
  • The accuracy of current tools for the rapid diagnosis of TBM is suboptimal.
  • We sought to develop a clinical-prediction rule for the diagnosis of TBM in a high HIV prevalence setting, and to compare performance outcomes to conventional diagnostic modalities and a novel lipoarabinomannan (LAM) antigen detection test (Clearview-TB®) using cerebrospinal fluid (CSF).
  • METHODS: Patients with suspected TBM were classified as definite-TBM (CSF culture or PCR positive), probable-TBM and non-TBM.
  • There were 39, 55 and 54 patients in the definite, probable and non-TBM groups, respectively.
  • The LAM sensitivity and specificity (95%CI) was 31% (17;48) and 94% (85;99), respectively (cut-point ≥ 0.18).
  • LAM positivity was associated with HIV co-infection and low CD4 T cell count (CD4<200 vs. >200 cells/µl; p = 0.03).
  • When LAM was combined with the clinical-prediction-rule, the sensitivity increased significantly (p<0.001) to 63% (47;68) and specificity remained high at 93% (82;98).
  • CONCLUSIONS: Despite its modest sensitivity the LAM ELISA is an accurate rapid rule-in test for TBM that has incremental value over smear-microscopy.
  • The rule-in value of LAM can be further increased by combination with a clinical-prediction rule, thus enhancing the rapid diagnosis of TBM in HIV-infected persons with advanced immunosuppression.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2009 Sep;59(3):167-87 [19643501.001]
  • [Cites] Scand J Infect Dis. 2009;41(3):188-94 [19235095.001]
  • [Cites] Infection. 2009 Dec;37(6):508-13 [19669088.001]
  • [Cites] AIDS. 2009 Sep 10;23(14):1875-80 [20108382.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):145-51 [19692904.001]
  • [Cites] PLoS One. 2010;5(3):e9848 [20352098.001]
  • [Cites] Curr Opin Pulm Med. 2010 May;16(3):262-70 [20375787.001]
  • [Cites] J Clin Microbiol. 2010 Aug;48(8):2972-4 [20534796.001]
  • [Cites] Am J Respir Crit Care Med. 2010 Aug 15;182(4):569-77 [20442433.001]
  • [Cites] Lancet Infect Dis. 2010 Nov;10(11):803-12 [20822958.001]
  • [Cites] Acta Neurol Scand. 2000 Jan;101(1):61-4 [10660155.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):289-99 [10675209.001]
  • [Cites] Am J Respir Crit Care Med. 2000 May;161(5):1713-9 [10806179.001]
  • [Cites] J Neuroimmunol. 2000 Nov 1;111(1-2):10-4 [11063816.001]
  • [Cites] J Microbiol Methods. 2001 May;45(1):41-52 [11295196.001]
  • [Cites] Scand J Infect Dis. 2001;33(4):279-84 [11345220.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Mar;9(2):344-7 [11874875.001]
  • [Cites] Clin Chest Med. 2002 Jun;23(2):351-4 [12092030.001]
  • [Cites] Lancet. 2002 Oct 26;360(9342):1287-92 [12414204.001]
  • [Cites] Lancet Infect Dis. 2003 Oct;3(10):633-43 [14522262.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):378-9 [14715783.001]
  • [Cites] JAMA. 1979 Jan 19;241(3):264-8 [102806.001]
  • [Cites] Acta Cytol. 1982 Sep-Oct;26(5):678-80 [6959457.001]
  • [Cites] J Hyg (Lond). 1986 Apr;96(2):231-8 [3084628.001]
  • [Cites] Medicine (Baltimore). 1987 Jul;66(4):317-26 [3600257.001]
  • [Cites] Infect Immun. 1991 May;59(5):1755-61 [1850379.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):668-72 [1346547.001]
  • [Cites] Am J Med. 1992 Nov;93(5):520-4 [1442854.001]
  • [Cites] Arch Intern Med. 1996 Aug 12-26;156(15):1710-6 [8694670.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):982-8 [8783697.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Oct;81(1):35-40 [8808639.001]
  • [Cites] Am J Med Sci. 1997 Jun;313(6):325-31 [9186145.001]
  • [Cites] Am J Trop Med Hyg. 1998 Jan;58(1):28-34 [9452288.001]
  • [Cites] QJM. 1998 Nov;91(11):743-7 [10024937.001]
  • [Cites] Neurol Clin. 1999 Nov;17(4):737-59 [10517926.001]
  • [Cites] J Clin Pathol. 1953 Aug;6(3):241-2 [13084774.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):234-7 [15609233.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):73-81 [15613948.001]
  • [Cites] J Infect Dis. 2005 Dec 15;192(12):2134-41 [16288379.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):2007-14 [16424233.001]
  • [Cites] Int J Tuberc Lung Dis. 2006 Jan;10(1):99-103 [16466045.001]
  • [Cites] J Clin Microbiol. 2006 Sep;44(9):3160-6 [16954242.001]
  • [Cites] Int J Infect Dis. 2007 Jul;11(4):348-54 [17321183.001]
  • [Cites] Thorax. 2007 Oct;62(10):911-8 [17675320.001]
  • [Cites] Clin Microbiol Rev. 2008 Apr;21(2):243-61, table of contents [18400795.001]
  • [Cites] Int J Tuberc Lung Dis. 2009 Oct;13(10):1253-9 [19793430.001]
  • (PMID = 21203513.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000231; United States / FIC NIH HHS / TW / D43TW00231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Lipopolysaccharides; 0 / lipoarabinomannan
  • [Other-IDs] NLM/ PMC3008727
  •  go-up   go-down


19. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood; 2005 Feb 15;105(4):1768-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
  • Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of histone H3 and H4 and of heat shock protein 90 (hsp90), increases p21 levels, as well as induces cell-cycle G(1) phase accumulation and apoptosis of the human chronic myeloid leukemia blast crisis (CML-BC) K562 cells and acute leukemia MV4-11 cells with the activating length mutation of FLT-3.
  • In the imatinib mesylate (IM)-refractory leukemia cells expressing Bcr-Abl with the T315I mutation, treatment with the combination attenuated the levels of the mutant Bcr-Abl and induced apoptosis.
  • Finally, cotreatment with LBH589 and 17-AAG also induced more apoptosis of IM-resistant primary CML-BC and acute myeloid leukemia (AML) cells (with activating mutation of FLT-3) than treatment with either agent alone.
  • [MeSH-major] Blast Crisis / metabolism. Enzyme Inhibitors / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Histone Deacetylase Inhibitors. Hydroxamic Acids / analogs & derivatives. Hydroxamic Acids / pharmacology. Leukemia, Myeloid / metabolism. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Rifabutin / analogs & derivatives. Rifabutin / pharmacology
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Benzamides. Benzoquinones. Cell Line, Tumor. Drug Combinations. Drug Synergism. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Gene Deletion. Gene Expression Regulation. Humans. Imatinib Mesylate. Indoles. K562 Cells. Lactams, Macrocyclic. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Piperazines / pharmacology. Point Mutation. Polyubiquitin / metabolism. Proteasome Endopeptidase Complex / metabolism. Pyrimidines / pharmacology. fms-Like Tyrosine Kinase 3

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. RIFABUTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15514006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95188
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Benzoquinones; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Lactams, Macrocyclic; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 120904-94-1 / Polyubiquitin; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin; 8A1O1M485B / Imatinib Mesylate; 9647FM7Y3Z / panobinostat; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


20. Meshinchi S, Arceci RJ: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist; 2007 Mar;12(3):341-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
  • Acute myeloid leukemia (AML) has posed significant therapeutic challenges to pediatric oncologists.
  • Despite intensive therapy, half of the children with AML relapse and die from their disease.
  • Efforts to identify risk factors in AML are directed toward defining populations who may benefit from alternative therapies.
  • Patients at lower risk for relapse may benefit from treatment de-escalation, sparing them adverse side effects.
  • Management of high-risk patients may prove more difficult, as the nearly myeloablative nature of AML therapy leaves little room for therapy escalation short of stem cell transplantation.
  • This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Risk Factors. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405900.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 133
  •  go-up   go-down


21. Fuh B, Lurito J, Grossi M, Daeschner C, Russo S: Bilateral internal carotid artery occlusions in a pediatric patient with refractory acute myeloid leukemia. Pediatr Blood Cancer; 2010 May;54(5):770-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral internal carotid artery occlusions in a pediatric patient with refractory acute myeloid leukemia.
  • Thromboembolism is a well-known complication of cancer including acute myeloid leukemia (AML) especially in patients with high myeloblast counts.
  • We report the case of a 3-year-old male with refractory AML who developed spontaneous bilateral internal carotid artery occlusion with diffuse cerebral infarcts.
  • [MeSH-major] Carotid Artery, Internal. Carotid Stenosis / etiology. Cerebral Infarction / etiology. Leukemia, Myeloid, Acute / complications

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052773.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol; 2007 Feb;136(4):624-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
  • The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation.
  • HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy.
  • The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Severity of Illness Index
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223919.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


23. Tseng MY, Chen YC, Lin YY, Chu SJ, Tsai SH: Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia. Am J Med Sci; 2010 Apr;339(4):387-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia.
  • Ocular involvement is not uncommon in patients with leukemia; however, bilateral CRVO as a complication of acute myeloid leukemia has rarely been reported.
  • Here, we report a patient who had simultaneous bilateral CRVO as the initial presentation of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Retinal Vein Occlusion / complications. Retinal Vein Occlusion / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186040.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


24. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer; 2007 Mar 15;109(6):1114-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
  • BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved.
  • Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach.
  • METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days) or hydroxyurea with or without all-trans retinoic acid (ATRA).
  • Patients who had adverse cytogenetics did not benefit.
  • Toxicity scores or supportive care requirements did not differ between the treatment arms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / adverse effects. Male. Middle Aged. Risk. Survival. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects


25. Sahu GR, Mishra R, Nagpal JK, Das BR: Notice of retraction. Alteration of p73 in acute myelogenous leukemia. Am J Hematol; 2008 Aug;83(8):691
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notice of retraction. Alteration of p73 in acute myelogenous leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionOf] Sahu GR, Mishra R, Nagpal JK, Das BR. Am J Hematol. 2005 May;79(1):1-7 [15849769.001]
  • (PMID = 18615454.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Retraction of Publication
  • [Publication-country] United States
  •  go-up   go-down


26. Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J, Paoletti F: Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol; 2009 Oct;37(10):1176-1185.e21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN.
  • OBJECTIVE: This study aimed to investigate the mechanisms of action of WEB-2170, an inverse agonist of platelet-activating factor receptor, capable of inducing apoptosis in human acute myelogenous leukemia (AML) cells.
  • MATERIAL AND METHODS: Gene expression profiling followed by cytofluorimetric, morphologic, and biologic analyses were used to monitor WEB-2170 effects in AML cell lines (ie, NB4, KG1, NB4-MR4, THP1, and U937) and blasts from patients with different AML (M0-M5) subtypes.
  • We have found that WEB-2170 triggered apoptosis in NB4, KG1, and NB4-MR4 cells where PTEN was expressed, but not in THP1 and U937 cells where PTEN was absent.
  • CONCLUSION: We demonstrated that WEB-2170 is a powerful antileukemic agent with interesting translational opportunities to treat AML and described mechanisms of drug-induced intrinsic and extrinsic apoptosis both in AML cell lines and blasts from AML patients by addressing PTEN as the master regulator of the whole process.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Azepines / pharmacology. Leukemia, Myeloid / pathology. Neoplasm Proteins / physiology. PTEN Phosphohydrolase / physiology. Triazoles / pharmacology
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Line, Tumor / drug effects. Female. G0 Phase / drug effects. Gene Expression Profiling. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / physiology. Humans. Male. Middle Aged. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Phosphorylation / drug effects. Polymerase Chain Reaction. Protein Processing, Post-Translational / drug effects. Protein Transport / drug effects. RNA Interference. RNA, Small Interfering / pharmacology. Young Adult


27. Montesinos JJ, Sánchez-Valle E, Flores-Figueroa E, Martínez-Jaramillo G, Flores-Guzmán P, Miranda-Peralta E, Gutiérrez-Romero M, Mayani H: Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines. Leuk Lymphoma; 2006 Jul;47(7):1379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines.
  • One has previously characterized two different hematopoietic cell populations (obtained by negative-selection) from normal bone marrow.
  • One has also characterized the chronic myeloid leukemia (CML) counterparts of these two populations and demonstrated functional deficiencies in terms of their growth in culture.
  • In keeping with this line of research, the goal of the present study was to obtain the same two populations (Populations I and II) from acute myeloid leukemia (AML) bone marrow and to characterize their biological behavior under the same culture conditions.
  • The results demonstrated that AML-derived Populations I and II were unable to proliferate in culture conditions that allowed significant proliferation of Populations I and II from normal marrow.
  • Population I from AML also showed a deficient expansion capacity; in contrast, Population II cells were able to expand to a similar extent to the one observed for Population II from normal marrow.
  • Both normal and AML populations were highly sensitive to the inhibitory effects of TNF-alpha; interestingly, whereas in normal fractions TNF-alpha showed a more pronounced inhibitory effect on more mature cells (Population I), this cytokine inhibited proliferation and expansion of AML Populations I and II in a similar degree.
  • It is noteworthy that the functional deficiencies observed in AML cells were even more pronounced than those previously reported for cultures of CML cells.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Cytokines / metabolism. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / biosynthesis. Antigens, CD38 / biosynthesis. Cell Culture Techniques / methods. Cell Proliferation. Culture Media, Serum-Free. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Male. Middle Aged. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923572.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Culture Media, Serum-Free; 0 / Cytokines; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


28. Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ: Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol; 2009 Feb;88(2):159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.
  • Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of adult acute myelogenous leukemia (AML) patients, mainly with a normal karyotype.
  • In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese AML patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.
  • The detection rate of NPM1 mutations in 220 AML patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.
  • Only one case each with an NPM1 mutation was detected in four M0, seven M1, five M6, and two M7 cases.
  • Further, 38.9% (14/36) patients with NPM1 mutations simultaneously exhibited internal tandem duplications in the FLT3 gene, and 66.7% (22/33) patients did not express CD34.
  • The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening AML, and for the quantitative analysis of minimal residual diseases.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics


29. Venizelos ID, Klonizakis I, Vlahaki E, Haralambidou S, Tatsiou Z, Ioannidou E: Skin relapse of acute myeloid leukemia associated with trisomy 8. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin relapse of acute myeloid leukemia associated with trisomy 8.
  • Acute myeloid leukemia (AML) is a morphologically diverse group of hematopoietic malignancies characterized by proliferation of immature cells that arise in the myeloid progenitor cells of the bone marrow.
  • It shows cutaneous lesions relatively rarely.
  • An association of AML with skin involvement and trisomy 8 has rarely been reported.
  • We present the case of a 74-year-old woman that presented with fatigue, nausea, dyspnea, and night sweats.
  • Accordingly, a diagnosis of AML involving the skin was made.
  • [MeSH-major] Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / pathology. Skin Neoplasms / pathology. Trisomy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992463.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


30. Aref S, El-Sherbiny M, Azmy E, Goda T, Selim T, El-Refaie M, Emaad T: Elevated serum endostatin levels is associated with favorable outcome in acute myeloid leukemia. Indian J Hematol Blood Transfus; 2008 Mar;24(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum endostatin levels is associated with favorable outcome in acute myeloid leukemia.
  • The levels and the prognostic relevance of serum endostatin in AML patient is not fully clear.
  • AIM: To evaluate serum levels of endostatin in acute myeloid leukemia patients before chemotherapy and after achieving complete remission and to correlate endostatin levels with patients outcome.
  • MATERIALS AND METHODS: Serum samples from 30 adult patients (22 males and 8 females, median age 37, range 19-66 years) with AML had been taken before chemotherapy was administered.
  • RESULTS: Endostatin serum levels were not significantly different in the pretreatment AML patients as compared to that in normal controls (P>0.05).
  • In AML patients the baseline endostatin levels were significantly lower than at CR (P=0.001).
  • No significant correlation were detected between pretreatment serum endostatin levels and age, peripheral blood white cell counts, platelet counts, bone marrow blast cell counts, blast cell distribution ratio.
  • The prognostic value of sE was also evaluated by dividing AML patients into high and low sE groups using the 75 percentile sE levels of the patients group as cutoff.
  • CONCLUSIONS: Elevated endostatin levels at AML diagnosis is a good prognostic marker for patients' outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25404-12 [9738008.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11721-6 [10206987.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3717-21 [10572084.001]
  • [Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1187-94 [10716919.001]
  • [Cites] Blood. 2000 Jul 1;96(1):282-7 [10891463.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):86-94 [12209593.001]
  • [Cites] Mediators Inflamm. 2003 Jun;12(3):167-71 [12857600.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8345-50 [14678995.001]
  • [Cites] J Surg Res. 2004 Jan;116(1):165-71 [14732364.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1312-7 [15931265.001]
  • [Cites] Neoplasma. 2005;52(2):182-4 [15800718.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):14-7 [11815955.001]
  • [Cites] Angiogenesis. 2002;5(1-2):111-8 [12549868.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):9-17 [12801293.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1159-65 [15130943.001]
  • (PMID = 23100932.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453162
  • [Keywords] NOTNLM ; AML / Angiogenesis / Endostatin / Prognosis
  •  go-up   go-down


31. Ma X, Chan EC: Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate. Bioconjug Chem; 2010 Jan;21(1):46-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate.
  • The purpose of our paper is to develop and validate a fluorescence-based mouse liver microsomal (MLM) assay in screening pharmaceutical reactive metabolites (RMs) using a glutathione (GSH)-conjugated 96-well plate.
  • Poly(2-hydroxyethylmethacrylate) (pHEMA) polymeric membrane was coated on 96-well plates to provide a functional support for GSH conjugation.
  • The subsequent RM screening of a series of marketed drugs and chemical compounds resulted in a range of TI values (1.0-25.7%) that corroborated with their capacity in generating RMs.
  • The differences of TI values are statistically significant between the compounds which are known to produce RMs and those that do not generate reactive intermediates.
  • [MeSH-major] Biological Assay / methods. Drug Evaluation, Preclinical / methods. Glutathione / chemistry. Luminescent Measurements / methods. Microsomes, Liver / metabolism. Pharmaceutical Preparations / analysis. Pharmaceutical Preparations / metabolism

  • MedlinePlus Health Information. consumer health - Medicines.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957910.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Imines; 0 / Pharmaceutical Preparations; 362O9ITL9D / Acetaminophen; G6S9BN13TI / N-acetyl-4-benzoquinoneimine; GAN16C9B8O / Glutathione
  •  go-up   go-down


32. Hack CE, Haber LT, Maier A, Shulte P, Fowler B, Lotz WG, Savage RE Jr: A Bayesian network model for biomarker-based dose response. Risk Anal; 2010 Jul;30(7):1037-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Bayesian network model was developed to integrate diverse types of data to conduct an exposure-dose-response assessment for benzene-induced acute myeloid leukemia (AML).
  • The network approach was used to evaluate and compare individual biomarkers and quantitatively link the biomarkers along the exposure-disease continuum.
  • The network-derived benchmark concentration was approximately an order of magnitude lower than that from the usual exposure concentration versus response approach, which suggests that the presence of more information in the low-dose region (where changes in biomarkers are detectable but effects on AML mortality are not) helps inform the description of the AML response at lower exposures.
  • This work provides a quantitative approach for linking changes in biomarkers of effect both to exposure information and to changes in disease response.
  • Such linkage can provide a scientifically valid point of departure that incorporates precursor dose-response information without being dependent on the difficult issue of a definition of adversity for precursors.
  • [MeSH-minor] Air Pollutants / toxicity. Dose-Response Relationship, Drug. Humans. Leukemia, Myeloid, Acute / chemically induced. Monte Carlo Method

  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412521.001).
  • [ISSN] 1539-6924
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Grant] United States / PHS HHS / / GS-10F-0369N
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Biomarkers; J64922108F / Benzene
  •  go-up   go-down


33. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol; 2005 Aug 20;23(24):5705-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
  • PURPOSE: Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML) and confer relatively favorable prognoses, these cytogenetic groups are often treated similarly.
  • PATIENTS AND METHODS: We analyzed 144 consecutive adults with t(8;21) and 168 with inv(16) treated on Cancer and Leukemia Group B front-line studies.
  • RESULTS: With a median follow-up of 6.4 years, for CBF AML as a whole, the CR rate was 88%, 5-year OS was 50% and CIR was 53%.
  • Unexpectedly, race was an important predictor for t(8;21) AML, in that nonwhites failed induction more often (odds ratio = 5.7; P = .006) and had shorter OS than whites when certain secondary cytogenetic abnormalities were present.
  • For inv(16) AML, secondary cytogenetic abnormalities (especially +22) and male sex predicted better outcome.
  • CONCLUSION: When the prognostic impact of race, secondary cytogenetic abnormalities, sex, and response to salvage treatment is considered, t(8;21) and inv(16) AMLs seem to be distinct clinical entities and should be stratified and reported separately.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Aged. Aziridines / administration & dosage. Benzoquinones / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Proportional Hazards Models. Prospective Studies. Remission Induction. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110030.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / K08-CA90469; United States / NCI NIH HHS / CA / P30-CA16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aziridines; 0 / Benzoquinones; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FQL5EUP13W / diaziquone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


34. LaFiura KM, Edwards H, Taub JW, Matherly LH, Fontana JA, Mohamed AN, Ravindranath Y, Ge Y, Children's Oncology Group: Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene; 2008 Aug 21;27(36):4933-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group.
  • t(8;21)(q22;q22) results in the AML1-ETO (A1E) fusion gene and is a common cytogenetic abnormality in acute myeloid leukemia (AML).
  • By RT-PCR amplifications and DNA sequencing, numerous in-frame and out-of-frame AML1b-ETO and AML1c-ETO transcripts were identified in 13 pediatric t(8;21) AMLs, likely resulting from alternate splicing, internal deletions and/or breakpoint region insertions involving both the AML1 (RUNX1) and ETO regions.
  • These structure alterations were found in AML1c-ETO but not AML1b-ETO transcripts in two adult t(8;21) AMLs.
  • When transfected into HeLa cells, only AML1b, and not the in-frame A1E forms, transactivated the GM-CSF promoter.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1999 Jun;78(6):251-64 [10422627.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Leukemia. 2005 Mar;19(3):367-72 [15674426.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1493-501 [16266896.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2063-71 [16107896.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2082-9 [16121218.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2072-81 [16136166.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Leukemia. 2006 Jun;20(6):987-93 [16598301.001]
  • [Cites] Nat Med. 2006 Aug;12(8):945-9 [16892037.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):624-8 [17610268.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] Gene. 2000 Mar 21;245(2):223-35 [10717473.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1201-7 [10914543.001]
  • [Cites] Cancer Invest. 2000;18(8):768-80 [11107447.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2072-7 [12357359.001]
  • [Cites] Cancer Invest. 2003;21(1):105-36 [12643014.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2746-55 [12842988.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4255-62 [15156181.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] Blood. 1993 Feb 15;81(4):883-8 [8427996.001]
  • [Cites] EMBO J. 1995 Jan 16;14(2):341-50 [7530657.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2762-9 [7651838.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2667-74 [8545124.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1139-42 [8683993.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1813-23 [8781439.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3604-11 [9584201.001]
  • [Cites] Gene. 1998 May 28;212(1):103-9 [9661669.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17186-91 [15569932.001]
  • (PMID = 18469864.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092308; United States / NCI NIH HHS / CA / CA30969; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / R01 CA076641; United States / NCI NIH HHS / CA / CA76641; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA92308
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA Primers; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS505499; NLM/ PMC3763903
  •  go-up   go-down


35. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J: Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem; 2007;14(5):601-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Strategies, which aim at inhibiting hyperactive signaling molecules, appear conceptually straight forward, but their translation into clinical practice has been hampered by many setbacks.
  • Understanding structure, function and regulation of this intracellular pathway as well as its crosstalk with other signaling activities in the cell will be essential to ensure reasonable usage of new therapeutic possibilities.
  • Signaling aberrations and signal transduction therapies will be discussed exemplary for two types of hematological neoplasia, acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346150.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 202
  •  go-up   go-down


36. Dick JE: Acute myeloid leukemia stem cells. Ann N Y Acad Sci; 2005 Jun;1044:1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia stem cells.
  • The concept that only a subpopulation of rare cancer stem cells (CSCs) is responsible for maintenance of the neoplasm emerged nearly 50 years ago; however, conclusive proof for the existence of a CSC was obtained only relatively recently.
  • The evidence for the existence of CSCs was first derived from the study of human acute myeloid leukemia (AML), largely because of the availability of quantitative stem cell assays for the leukemic stem cell (LSC).
  • These studies showed that only rare cells within the leukemic clone had the capacity to initiate AML growth after transplant into NOD/SCID mice, establishing the hierarchical organization of AML.
  • These findings have important implications for our understanding of the leukemogenic process as well as the design of more effective therapies to eliminate AML based on eradication of the LSCs.
  • [MeSH-major] Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / physiology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Animals. Humans. Neoplastic Stem Cells / classification. Neoplastic Stem Cells / pathology. Neoplastic Stem Cells / transplantation


37. Lemez P, Urbánek V: Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma; 2005;52(5):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
  • The aim was to follow-up gonadal functions in long-term survivors of acute myeloid leukemias (AML) after intensive chemotherapy based on high-doses of cytosine arabinoside (Ara-C) and anthracyclines in the study UHKT-911.
  • Adult patients were treated with at least 3 cycles of chemotherapy including 1-3 courses of Ara-C 10 x 2000 mg/m2/12 h and daunorubicin (DNR) 2 x 45 mg/m2/d.
  • The semen of a 49-year-old patient contained normal numbers of spermatozoa with decreased velocity when examined 1 year after chemotherapy but 4 years later exhibited oligoasthenozoospermia.
  • The patient received 4 cycles of Ara-C and DNR plus one cycle with etoposide 350 mg/m2 and mitoxantrone 30 mg/m2.
  • Semen examination of two patients 55- and 59-year-old showed permanent oligoasthenozoospermia with only sporadic progressively motile spermatozoa which might not be compatible with fertilization by sexual intercourse.
  • They received the same chemotherapy including cumulative doses of etoposide 500 mg/m2 and mitoxantrone 36 mg/m2.
  • Permanent amenorrhea developed in two women (42- and 46-year-old) during chemotherapy with DNR, Ara-C, etoposide, and mitoxantrone which was not the case in three women (29-40 years old) treated without etoposide and mitoxantrone.
  • Intensive chemotherapy with high-doses of Ara-C and DNR plus one cycle of etoposide and mitoxantrone may cause permanent gonadal dysfunction in middle-aged patients with AML.
  • [MeSH-major] Amenorrhea / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid / drug therapy. Spermatozoa / drug effects
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow Transplantation. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Oligospermia / chemically induced. Sperm Motility / drug effects

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151584.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


38. Tadmor T, Vadazs Z, Dar H, Laor R, Attias D: Hemophagocytic syndrome preceding acute myeloid leukemia with der t [7:17][q12; q11], monosomy, 17 and 5p-. J Pediatr Hematol Oncol; 2006 Aug;28(8):544-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemophagocytic syndrome preceding acute myeloid leukemia with der t [7:17][q12; q11], monosomy, 17 and 5p-.
  • Hemophagocytic syndrome (HS) is a severe and acute proliferative process of histiocytes, often associated with infection or malignancy.
  • No consistent clonal abnormality has been reported in HS.
  • We report a case of a child presented with HS, who progressed later to acute myeloid leukemia (AML)-M4, associated with a clonal evolution, from normal to a complex karyotype consisting of t [7:17] and deletions in chromosomes 7, 17, and 5.
  • This is the second report of involvement of 7q rearrangement in a child with HS that has progressed to AML.
  • Additional studies are required to establish the association reported here, between HS with progression to AML and chromosome rearrangements that involve chromosome 7q.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 7 / genetics. Leukemia, Myeloid / genetics. Lymphohistiocytosis, Hemophagocytic / genetics
  • [MeSH-minor] Acute Disease. Child, Preschool. Fatal Outcome. Humans. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912598.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Yenson PR, Forrest D, Schmiegelow K, Dalal BI: Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am J Hematol; 2008 Jan;83(1):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
  • We present such a patient who was a slow metabolizer for azathioprine, and developed a rapidly lethal form acute myeloid leukemia after relatively low dose exposure to the drug.
  • [MeSH-major] Azathioprine / adverse effects. Azathioprine / therapeutic use. Crohn Disease / drug therapy. Leukemia, Myeloid, Acute / pathology. Methyltransferases / deficiency. Methyltransferases / metabolism


40. Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W: Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood; 2009 Apr 23;113(17):3903-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
  • Dose density during early induction has been demonstrated to be one of the prime determinants for treatment efficacy in acute myeloid leukemia (AML).
  • The German AML Cooperative Group has therefore piloted a dose-dense induction regimen sequential high-dose AraC and mitoxantrone followed by pegfilgrastim (S-HAM) in which 2 induction cycles are applied over 11 to 12 days instead of 25 to 29 days as used in conventional double induction, thereby increasing dose density 2-fold.
  • Of 172 de novo AML patients (excluding acute promyelocytic leukemia), 61% reached a complete remission, 22% a complete remission with incomplete peripheral recovery, 7% had persistent leukemia, 10% died (early death) resulting in an overall response rate of 83%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / therapeutic use. Neutropenia / chemically induced

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131552.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


41. Huang Y, Li WJ, Wei CX, Zhou Z, Nie B: [Expression of HoxA10 in acute leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec;13(6):959-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of HoxA10 in acute leukemia and its significance].
  • To investigate the expression of HoxA(10) mRNA in acute leukemia patients and its significance, HoxA(10) level was detected by reverse transcription polymerase chain reaction (RT-PCR) in 50 patients with acute leukemias, 7 healthy volunteers and 3 patients with ITP (idiopathic thrombocytopenic purpura).
  • The regularity of the expression of HoxA(10) gene in acute leukemia and the relationship between HoxA(10) level and the prognosis of leukemia was explored.
  • The results showed that HoxA(10) was expressed in all types of acute myelogenous leukemia; HoxA(10) message was also observed in acute lymphoblastic leukemia patients and part of control groups.
  • 3 normal donors were found not to express HoxA(10).
  • The level of HoxA(10) mRNA of acute myelogenous leukemia patients was significantly higher than that of acute lymphoblastic leukemia patients and controls (P < 0.01).
  • HoxA(10) gene appeared to be more strongly expressed in AML-M(1) and -M(2) subtypes than in AML-M(4) and -M(5) subtypes, and the gene was notable high expressed in acute promyelocytic leukemia.
  • The level of HoxA(10) of 9 non-responsive patients was higher than that of 8 remission patients, but there was no significant difference between them (P = 0.258).
  • HoxA(10) was overexpressed in acute myelogenous leukemia.
  • It is concluded that HoxA(10) is a major transcription factor regulating hematopoiesis and a mark to differentiate lymphoid leukemia and myelogenous leukemia, but not a specific gene of cancer.
  • The level of HoxA(10) is related with load of leukemic cells and curative effect, and can affect occurrence and development of leukemia in combination with many cytokines, HoxA(10) may facilitate the leukemia progression with another cofactors.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403259.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 140441-81-2 / HOXA10 protein, human
  •  go-up   go-down


42. Wykrzykowska JJ, Carrozza J, Laham RJ: Aortocoronary dissection with acute left main artery occlusion: successful treatment with emergent stenting. J Invasive Cardiol; 2006 Aug;18(8):E217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortocoronary dissection with acute left main artery occlusion: successful treatment with emergent stenting.
  • Of the type-A dissections in the International Registry of Aortic Dissections (IRAD), 27% were caused by coronary interventions.
  • [MeSH-major] Aneurysm, Dissecting / therapy. Aortic Aneurysm / therapy. Coronary Aneurysm / therapy. Coronary Disease / therapy. Stents

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877790.001).
  • [ISSN] 1557-2501
  • [Journal-full-title] The Journal of invasive cardiology
  • [ISO-abbreviation] J Invasive Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Evrard AS, Hémon D, Billon S, Laurier D, Jougla E, Tirmarche M, Clavel J: Ecological association between indoor radon concentration and childhood leukaemia incidence in France, 1990-1998. Eur J Cancer Prev; 2005 Apr;14(2):147-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ecological association between indoor radon concentration and childhood leukaemia incidence in France, 1990-1998.
  • The objective of this study was to evaluate the ecological association between indoor radon concentration and acute leukaemia incidence among children under 15 years of age in the 348 geographical units (zones d'emploi, ZE) of France between 1990 and 1998.
  • During that period, 4015 cases were registered by the French National Registry of Childhood Leukaemia and Lymphoma.
  • A positive ecological association, on the borderline of statistical significance (P=0.053), was observed between indoor radon concentration and childhood leukaemia incidence.
  • The association was highly significant for acute myeloid leukaemia (AML) (P=0.004) but not for acute lymphocytic leukaemia (ALL) (P=0.49).
  • The standardized incidence ratio (SIR) increased by 7, 3 and 24% for all acute leukaemia, ALL and AML, respectively, when radon concentration increased by 100 Bq/m.
  • In conclusion, the present ecological study supports the hypothesis of a moderate association between indoor radon concentration and childhood acute myeloid leukaemia.
  • Since the association is moderate, this result does not appear inconsistent with the five published case-control studies, most of which found no significant association.
  • [MeSH-major] Air Pollution, Indoor / adverse effects. Environmental Exposure. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Radon / adverse effects. Registries / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • MedlinePlus Health Information. consumer health - Radon.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785319.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q74S4N8N1G / Radon
  •  go-up   go-down


44. Dawson MA, Avery S, McQuilten ZK, Bailey MJ, Shortt J, Polizzotto MN, Wood EM, Cole-Sinclair MF: Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough? Haematologica; 2007 Jul;92(7):996-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?
  • Although essential in the management of AML, there is little information quantitating transfusion requirements for these patients.
  • We evaluated 111 consecutive adults treated for AML, showing that approximately 150 blood donors are required to adequately cater for a single patient's complete therapy with little variation for age, prognostic group or intensity of treatment.
  • [MeSH-major] Blood Transfusion / utilization. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols. Blood Donors / supply & distribution. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606456.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Leslie M, Case MC, Hall AG, Coulthard SA: Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br J Haematol; 2006 Mar;132(6):740-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia.
  • L-asparaginase is active in the treatment of acute lymphoblastic leukaemia (ALL) through the depletion of serum asparagine.
  • Here we report that median asparagine synthetase (AS) mRNA levels were higher in acute myeloid leukaemia (AML) than ALL blasts in both children and adults, with intermediate levels in normal peripheral blood mononuclear cells (NPBMC).
  • NPBMC versus child ALL (Tukeys multiple comparison test, P < 0.05); child ALL versus child AML (P < 0.001) and adult ALL versus adult AML (P < 0.01) were all significant and support the hypothesis that selectivity to treatment with l-asparaginase is due, at least in part, to lower AS expression.
  • [MeSH-major] Aspartate-Ammonia Ligase / analysis. Lymphocytes / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Infant. Leukemia, Myeloid / enzymology. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487174.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


46. Wandroo F, Stableforth P, Hasan Y: Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated with voriconazole. Clin Lab Haematol; 2006 Apr;28(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated with voriconazole.
  • [MeSH-major] Aspergillosis / drug therapy. Aspergillus fumigatus. Brain Abscess / drug therapy. Central Nervous System Fungal Infections / drug therapy. Leukemia, Erythroblastic, Acute / drug therapy. Pyrimidines / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630219.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


47. Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø: Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol; 2009 Jan;144(1):53-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.
  • Bone marrow angiogenesis is suggested to play a role in the pathogenesis of acute myeloid leukaemia (AML) and endothelial cells may mediate chemosensitivity.
  • This study investigated in vitro endothelial effects of coculture of microvascular endothelial cells (MVEC) with AML cells derived from 33 consecutive AML patients.
  • A proliferation assay showed that (i) AML cells from the majority of patients examined increased endothelial cell proliferation, while cytokine neutralizing experiments had divergent effects on proliferation and (ii) the angiopoietin/Tie2 system was important for growth of AML cells, and angiopoietin-1 induced phosphorylation of signal transducers and activators of transcription (STAT) proteins in AML cells.
  • Finally, gene expression profiling of MVEC cocultured with AML cells was conducted in non-contact cultures.
  • Microarray analysis revealed that the majority of significantly expressed genes could be categorized into gene ontology terms involved in transcription, cellular organization and intracellular signalling.
  • Our study indicates a role for the leukaemic-endothelium crosstalk in leukaemogenesis with enhancement of endothelial cell growth and increased AML cell proliferation possibly mediated by angiopoietin-1 and the STAT signalling pathway.
  • [MeSH-major] Angiopoietin-1 / metabolism. Endothelial Cells / pathology. Leukemia, Myeloid, Acute / pathology. STAT Transcription Factors / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Proliferation. Chemokine CXCL10 / genetics. Chemokine CXCL11 / genetics. Chemokine CXCL9 / genetics. Coculture Techniques. Female. Gene Expression Profiling. Humans. Interleukin-8 / genetics. Lung / blood supply. Male. Microcirculation. Middle Aged. Molecular Sequence Data. Neovascularization, Pathologic. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Up-Regulation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016730.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiopoietin-1; 0 / Chemokine CXCL10; 0 / Chemokine CXCL11; 0 / Chemokine CXCL9; 0 / Interleukin-8; 0 / STAT Transcription Factors
  •  go-up   go-down


48. Ozdogu H, Boga C, Kizilkilic E, Kozanoglu I, Karakus S, Sahin FI, Unalan D, Haberal M: The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center. Transplant Proc; 2007 May;39(4):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
  • Autologous stem cell transplantation is the current standard approach for patients with multiple myeloma and relapsed or refractory lymphoma.
  • Nonmyeloablative allogeneic stem cell transplantation has been applied worldwide.
  • Seven evaluable patients younger than 65 years old with stage II/III multiple myeloma were treated with high-dose melphalan therapy (140 mg/m(2)) plus autologous peripheral blood stem cell transplantation.
  • At a median follow-up of 10 months, all patients remained disease-free.
  • Four patients with acute myeloblastic leukemia underwent nonmyeloablative allogeneic peripheral stem cell transplantation.
  • All patients received fully matched blood from a related donor 2 days after chemotherapy in conjunction with graft-versus-host disease prophylaxis.
  • All other patients in remission remained with >90% donor cell engraftment.
  • These patients are disease-free at 13, 10, and 2 months.
  • [MeSH-major] Hematologic Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods. Transplantation, Autologous
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Communicable Disease Control. Cyclosporine / therapeutic use. Female. Hematopoietic Stem Cell Mobilization. Humans. Immunosuppressive Agents / therapeutic use. Male. Melphalan / therapeutic use. Middle Aged. Mitoxantrone / therapeutic use. Patient Selection. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524948.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


49. Ciurea SO, Andersson BS: Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2009 May;15(5):523-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Busulfan in hematopoietic stem cell transplantation.
  • The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies.
  • Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy.
  • Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers.
  • The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUSULFAN .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361744.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055164; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 2P01 CA55164; United States / NCI NIH HHS / CA / 2P30CA16672-26
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; G1LN9045DK / Busulfan
  • [Number-of-references] 115
  • [Other-IDs] NLM/ NIHMS111769; NLM/ PMC4261695
  •  go-up   go-down


50. Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES: Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol Cancer Ther; 2010 Oct;9(10):2737-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
  • The efficacy of aflibercept alone and in combination with doxorubicin was evaluated in human VEGF-expressing acute myeloid leukemia (AML) cell lines and primary cells xenotransplanted into immunodeficient mice.
  • Aflibercept reduced primary VEGF/VEGFR-positive AML colony formation growth in vitro and inhibited AML xenograft growth up to 93% in association with antiangiogenic and antiproliferative effects, hypoxia, and VEGF sequestration in multiple models.
  • High VEGF-A expression by AML cells promoted in vivo xenograft growth and aflibercept sensitivity.
  • Aflibercept therapy slowed disease progression in two systemic human AML xenograft models and reduced peripheral leukemia disease in a primary relapsed AML model in NOD/SCID/IL2Rγnull mice.
  • Sequential aflibercept followed by doxorubicin resulted in progressive anthracycline accumulation in marrow and extramedullary AML sites and resulted in 2-fold higher drug levels 24 hours after administration.
  • These data suggest that inefficient drug delivery by leukemia-associated vasculature may mediate chemoresistance and support further clinical evaluation of combination aflibercept and anthracycline therapy in refractory/relapsed AML patients.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Recombinant Fusion Proteins / pharmacology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924124.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA016156
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Recombinant Fusion Proteins; 15C2VL427D / aflibercept; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


51. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M: Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res; 2007 Apr 1;67(7):3210-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
  • Activation of the Raf/MEK/ERK pathway and inactivation of wild-type p53 by Mdm2 overexpression are frequent molecular events in acute myelogenous leukemia (AML).
  • We investigated the interaction of Raf/MEK/ERK and p53 pathways after their simultaneous blockades using a selective small-molecule antagonist of Mdm2, Nutlin-3a, and a pharmacologic MEK-specific inhibitor, PD98059.
  • We found that PD98059, which itself has minimal apoptogenic activity, acts synergistically with Nutlin-3a to induce apoptosis in wild-type p53 AML cell lines OCI-AML-3 and MOLM-13.
  • In accordance with the activation of transcription-dependent apoptosis, PD98059 treatment promoted the translocation of p53 from the cytoplasm to the nucleus in OCI-AML-3 cells, in which p53 primarily initiates transcription-independent apoptosis when cells are treated with Nutlin-3a alone.
  • [MeSH-major] Apoptosis / physiology. Leukemia, Myeloid, Acute / enzymology. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / enzymology. Cell Nucleus / physiology. Drug Synergism. Fatty Acids, Unsaturated / pharmacology. Flavonoids / pharmacology. Humans. Imidazoles. Piperazines. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Transcription, Genetic. raf Kinases / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409429.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA49639; United States / NCI NIH HHS / CA / CA89346; United States / NCI NIH HHS / CA / P01 CA55164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Fatty Acids, Unsaturated; 0 / Flavonoids; 0 / Imidazoles; 0 / Piperazines; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 87081-35-4 / leptomycin B; EC 2.7.11.1 / raf Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


52. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G: The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy; 2010 Oct;6(7):976-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
  • We analyzed the cellular and molecular effects of two different histone deacetylase inhibitors (HDACi), MGCD0103 and vorinostat, in combination with GX15-070, a BH3-mimetic, in acute myeloid leukemia (AML) cell lines and primary AML cells, and demonstrated that the combination has a synergistic antileukemia effect.
  • We observed that in addition to apoptosis, autophagy also accounts for the observed nonapoptotic decrease of cell viability.
  • These findings reveal that for this specific combination, autophagy plays a positive role in inducing cytotoxicity, and that the involved ER signaling networks, as well as their clinical relevance, should be further studied in both preclinical and clinical trials of leukemia and other malignancies.
  • [MeSH-major] Apoptosis / drug effects. Autophagy / drug effects. Histone Deacetylase Inhibitors. Leukemia, Myeloid, Acute / drug therapy. Pyrroles
  • [MeSH-minor] BH3 Interacting Domain Death Agonist Protein / metabolism. Benzamides / pharmacology. Benzamides / therapeutic use. Cell Line, Tumor / drug effects. Drug Synergism. Humans. Hydroxamic Acids / pharmacology. Hydroxamic Acids / therapeutic use. Pyrimidines / pharmacology. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729640.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Benzamides; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Pyrimidines; 0 / Pyrroles; 0 / obatoclax; 58IFB293JI / vorinostat; A6GWB8T96J / mocetinostat
  •  go-up   go-down


53. Yang Y, Tian Y, Yan C, Jin X, Tang J, Shen X: Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia. Environ Toxicol; 2009 Oct;24(5):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia.
  • The 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, not only is a widely used biomarker for the measurement of endogenous oxidative DNA damage, but might also be a risk factor for many diseases including cancer.
  • In the present study, the level of urinary 8-OHdG was examined in 116 Chinese children with acute leukemia (94 acute lymphoid leukemia, ALL, 22 acute myeloid leukemia, AML), and its correlation with urinary metal elements was investigated.
  • Our result showed that the level of urinary 8-OHdG in children with acute leukemia before treatment was significantly elevated compared with that in normal controls (11.92 +/- 15.42 vs. 4.03 +/- 4.70 ng/mg creatinine, P < 0.05).
  • In particular, urinary 8-OHdG was higher in children with acute leukemia aged under 3 years (20.86 +/- 21.75 ng/mg creatinine) than in those aged 3-15 years (8.09 +/- 9.65 ng/mg creatinine), whereas no differences were shown in terms of gender, parental smoking and education, household income, place of residence, and use of paracetamol.
  • In addition, urinary 8-OHdG levels were similar among different subtypes of acute lymphoid leukemia (ALL) patients.
  • Furthermore, linear regression analysis revealed a significant correlation between urinary 8-OHdG and urinary Cr, but not Fe or As, in group aged <3 years compared with group aged 3-15 years (P = 0.041), indicating that the metal elements may be involved in increasing urinary 8-OHdG level in younger children with acute leukemia.
  • Our results suggest that children with acute leukemia undergo an increased risk of oxidative DNA damage, which may be correlated with high level of Cr exposure in Chinese children with acute leukemia.
  • [MeSH-major] Carcinogens / metabolism. Deoxyguanosine / analogs & derivatives. Leukemia, Myeloid, Acute / urine. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979530.001).
  • [ISSN] 1522-7278
  • [Journal-full-title] Environmental toxicology
  • [ISO-abbreviation] Environ. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Metals; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


54. Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S: Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol; 2010 Mar;38(3):180-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
  • OBJECTIVE: Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML).
  • Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AML blasts toward chemotherapy.
  • The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition.
  • MATERIALS AND METHODS: We used primary blasts from patients with FLT3-ITD or FLT3 wild-type AML.
  • Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells on bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts.
  • Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD.
  • CONCLUSION: CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden may provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20035824.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / Z01 AI000988; United States / Intramural NIH HHS / / Z01 AI000988-02; United States / Intramural NIH HHS / / ZIA AI000988-03; United States / Intramural NIH HHS / / ZIA AI000988-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / Tumor Suppressor Proteins; 155148-31-5 / JM 3100; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS762780; NLM/ PMC4777334
  •  go-up   go-down


55. ZHANG LW, WANG Y, ZHANG CH: [A case with severity stenosis of left main artery manifested with recurrent syncope]. Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep;38(9):844-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aortic Valve Stenosis / diagnosis. Syncope / diagnosis

  • MedlinePlus Health Information. consumer health - Fainting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092658.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


56. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res; 2008 Sep 1;14(17):5619-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
  • PURPOSE: Bexarotene is a retinoic X receptor agonist that has been shown in vitro to inhibit growth and induce differentiation of myeloid leukemic cell lines.
  • We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML).
  • EXPERIMENTAL DESIGN: We enrolled patients with active non-M3 AML who had either relapsed or refractory disease or were not eligible for standard cytotoxic chemotherapy.
  • Cohorts of three to six patients received escalating doses of daily oral bexarotene ranging from 100 to 400 mg/m(2) until evidence of disease progression or unacceptable adverse events occurred.
  • Three patients with relapsed AML survived >1 year while taking bexarotene.
  • Leukemic blast differentiation was suggested by the presence of the leukemic cytogenetic abnormality in mature circulating granulocytes and the occurrence of differentiation syndrome.
  • Bexarotene is well tolerated in patients with non-M3 AML and has evidence of antileukemic activity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Retinoid X Receptors / antagonists & inhibitors. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Leukemia, Promyelocytic, Acute / drug therapy. Male. Maximum Tolerated Dose. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Sep 1;14(17):5311-3 [18765520.001]
  • (PMID = 18765556.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoid X Receptors; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


57. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, Young BD, Rohatiner AZ, Lister TA, Bonnet D: AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood; 2006 Feb 01;107(3):1166-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.
  • We explored why 51% of 59 acute myeloid leukemia (AML) patients were unable to initiate leukemia in NOD/SCID mice.
  • Increasing the cell dose, using more permissive recipients, and alternative tissue sources did not cause AML engraftment in most previously nonengrafting AML samples.
  • Homing of AML cells to the marrow was the same between engrafters and nonengrafters.
  • The only variable that was related to engraftment ability was the karyotypically defined risk stratification of individual AML cases.
  • Of interest, follow-up of younger patients with intermediate-risk AML revealed a significant difference in overall survival between NOD/SCID engrafting and nonengrafting AMLs.
  • Hence, the ability of AML to engraft in the NOD/SCID assay seems to be an inherent property of AML cells, independent of homing, conditioning, or cell frequency/source, which is directly related to prognosis.
  • Our results suggest an important difference between leukemic initiating cells between engrafting and nonengrafting AML cases that correlates with treatment response.
  • [MeSH-major] Biological Assay. Graft Survival. Leukemia, Myeloid, Acute. Neoplastic Stem Cells. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Blood. 2000 May 15;95(10):3102-5 [10807775.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3289-96 [10828007.001]
  • [Cites] Exp Hematol. 2000 Jun;28(6):660-71 [10880752.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] J Clin Invest. 2001 Jan;107(2):199-206 [11160136.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):1076-7 [11442505.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1818-26 [12200698.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1992-2003 [12357350.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2905-13 [12411299.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Stem Cells. 2004;22(2):188-201 [14990858.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2942-9 [15070669.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2817-24 [15087398.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4754-61 [8639846.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5320-5 [9144235.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4523-30 [9616148.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4325-35 [9834239.001]
  • [Cites] Science. 1999 Feb 5;283(5403):845-8 [9933168.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1761-72 [10477702.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Blood. 2005 Aug 1;106(3):899-902 [15831697.001]
  • [Cites] Leukemia. 2000 May;14(5):889-97 [10803522.001]
  • (PMID = 16234360.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6438; United Kingdom / Cancer Research UK / / A6789; United States / NHLBI NIH HHS / HL / HL-64856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC1895911
  •  go-up   go-down


58. Shabbir M, Stuart R: Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs; 2010 Mar;19(3):427-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMPORTANCE OF THE FIELD: Internal tandem duplication of the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) is a common recurring mutation in acute myeloid leukemia (AML) with normal karyotype, and the presence of FLT3-ITD confers a poor prognosis on this large subgroup of AML patients.
  • AREAS COVERED IN THIS REVIEW: An extensive literature search was conducted that included published articles and abstracts on the preclinical and clinical development of this agent spanning the last decade.
  • TAKE HOME MESSAGE: Lestaurtinib is a multi targeted tyrosine kinase inhibitor which has been shown to potently inhibit FLT3 at nanomolar concentrations in preclinical studies, leading to its rapid development as a potential targeted agent for treatment of AML.
  • Currently, Phase II and Phase III studies are underway aiming to establish the future of this agent as a treatment option for patients with FLT3-ITD AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carbazoles / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141349.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Protein Kinase Inhibitors; DO989GC5D1 / lestaurtinib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 63
  •  go-up   go-down


59. Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD: Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer; 2006 Feb;46(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
  • PURPOSE: A previous Pediatric Oncology Group (POG) study showed high incidence of secondary acute myelogenous leukemia (AML) in children treated for T-cell acute lymphoblastic leukemia (T-ALL) or higher-stage lymphoblastic lymphoma.
  • To prevent secondary neoplasms, induce prolonged asparagine depletion, and maintain high event-free survival (EFS) in children with newly diagnosed T-ALL or higher-stage non-Hodgkins lymphoma (NHL), we designed this pilot study to determine feasibility and safety of substituting methotrexate/mercaptopurine for teniposide/cytarabine and PEG-asparaginase for native asparaginase.
  • One patient taken off study for asparaginase toxicity was treated with multiagent therapy that contained teniposide, and died from secondary myelodysplasia (sMDS)/AML.
  • EFS was not compromised and secondary neoplasms were decreased.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Anthracyclines / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Disease-Free Survival. Drug Hypersensitivity / etiology. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Male. Pilot Projects. Remission Induction. Sepsis / etiology. Sepsis / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007607.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA5312; United States / NCI NIH HHS / CA / CA29139
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


60. Bhayat F, Das-Gupta E, Hubbard R: Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study. BMC Cancer; 2010;10:514
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study.
  • BACKGROUND: We have previously shown that in the UK mortality in people with Acute Myeloid Leukaemia (AML) was nearly 50% greater among the most socio-economically deprived.
  • The aim of this study was to determine whether AML patients from lower socioeconomic classes had a lower chance of receiving a bone marrow transplant.
  • METHODS: Using Hospital Episode Statistics (HES) data, we identified all incident cases of AML admitted to UK hospitals between 1998 and 2007.
  • We calculated the number of bone marrow transplantations undertaken in AML patients, stratifying our results by gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity.
  • We used logistic regression to calculate odds ratios for bone marrow transplantation, adjusting for gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity score.
  • RESULTS: We identified a total of 23 910 incident cases of AML over this 10-year time period, of whom 1 140 (4.8%) underwent BMT.
  • Bone marrow transplantation declined with increasing socioeconomic deprivation (p for trend < 0.001) such that people in the most deprived socioeconomic quintile were 40% less likely to have a transplant than those in the most advantaged group (Odds Ratio 0.60, 95% confidence interval 0.49, 0.73), even after adjusting for gender, age at diagnosis, year of diagnosis and co-morbidity.
  • CONCLUSION: This large cohort study demonstrates that AML patients from lower socioeconomic classes are less likely to undergo bone marrow transplantation than their better off counter-parts.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / therapy


61. Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY: Oxaliplatin-related acute myelogenous leukemia. Oncologist; 2006 Mar;11(3):261-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-related acute myelogenous leukemia.
  • Bone marrow biopsy was consistent with therapy-related acute myelogenous leukemia.
  • It is likely that the leukemia was related to the oxaliplatin administration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549810.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


62. Sollars VE, Pequignot E, Rothstein JL, Buchberg AM: Analysis of expansion of myeloid progenitors in mice to identify leukemic susceptibility genes. Mamm Genome; 2006 Aug;17(8):808-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of expansion of myeloid progenitors in mice to identify leukemic susceptibility genes.
  • The myeloid progenitor cell compartment (MPC) exhibits pronounced expansion in human myeloid leukemias.
  • It is becoming more apparent that progression of myelodysplastic syndromes and myeloproliferative diseases to acute myelogenous leukemia is the result of defects in progenitor cell maturation.
  • The MPC of bone marrow was analyzed in mice using a cell culture assay for measuring the relative frequency of proliferative myeloid progenitors.
  • The SWR/J and FVB/J strains show consistently low frequencies of myeloid progenitors, while the DBA/2J and SJL/J inbred strains show consistently high frequencies of myeloid progenitors within the bone marrow compartment.
  • Given the importance of this cell compartment in leukemia progression and the soon to be released genomic sequence of 15 mouse strains, these differences may provide a valuable tool for research into leukemia.
  • [MeSH-major] Cell Proliferation. Genetic Predisposition to Disease. Leukemia / genetics. Myeloid Progenitor Cells / metabolism
  • [MeSH-minor] Animals. Bone Marrow / growth & development. Cell Size. Chromosomes, Mammalian. Cytokines / metabolism. Flow Cytometry. Linkage Disequilibrium. Male. Mice. Mice, Inbred Strains. Stem Cells

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jan 15;99(2):561-6 [11781239.001]
  • [Cites] Cancer Res. 1989 Jan 1;49(1):149-53 [2783241.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2343-50 [14630819.001]
  • [Cites] Annu Rev Immunol. 1990;8:303-33 [1693082.001]
  • [Cites] PLoS Biol. 2004 Dec;2(12):e393 [15534693.001]
  • [Cites] FASEB J. 1999 Apr;13(6):707-13 [10094931.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1274-81 [11222370.001]
  • [Cites] J Virol. 1981 Aug;39(2):632-40 [6268848.001]
  • [Cites] Blood. 1995 May 1;85(9):2331-6 [7727767.001]
  • [Cites] Blood. 1999 May 15;93(10):3294-301 [10233881.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3947-54 [12010793.001]
  • [Cites] Exp Hematol. 2000 Apr;28(4):442-50 [10781902.001]
  • [Cites] Exp Hematol. 1999 May;27(5):928-35 [10340409.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1141-50 [8642256.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):117-22 [12524234.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):920-6 [9217198.001]
  • [Cites] J Exp Med. 1997 Aug 18;186(4):529-36 [9254651.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):639-45 [6652681.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1543-50 [9057635.001]
  • [Cites] Science. 2001 Jun 8;292(5523):1915-8 [11397946.001]
  • [Cites] Physiol Genomics. 2002 Dec 3;11(3):185-93 [12419856.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Mamm Genome. 2003 Jan;14(1):81-5 [12532271.001]
  • [Cites] J Virol. 1984 Sep;51(3):586-94 [6088784.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1720-3 [7691233.001]
  • [Cites] J Virol. 1988 Mar;62(3):839-46 [2828679.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):399-402 [8275475.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):348-53 [10610183.001]
  • [Cites] J Mol Cell Immunol. 1987;3(1):29-36 [3509920.001]
  • [Cites] Blood. 2003 Jul 1;102(1):94-101 [12623852.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2736-44 [9108391.001]
  • [Cites] J Virol. 1982 May;42(2):379-88 [6283161.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2446-8 [10733521.001]
  • [Cites] Cell Struct Funct. 2002 Apr;27(2):81-9 [12207049.001]
  • [Cites] Stem Cells. 2002;20(5):460-9 [12351816.001]
  • [Cites] Blood. 1991 Aug 15;78(4):961-6 [1714329.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2449-51 [10733522.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):881-90 [15781580.001]
  • (PMID = 16897342.001).
  • [ISSN] 0938-8990
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32-CA09678
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


63. Lim AY, Gaffney K, Scott DG: Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford); 2005 Aug;44(8):1051-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancytopenia was defined as white blood cell count (WBC) <3.5 x 10(9)/l, haemoglobin (Hb) <11 g/dl and platelet count <130 x 10(9)/l.
  • There were seven deaths (28% mortality), five from sepsis and two from acute myeloid leukaemia.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rheumatology (Oxford). 2006 Mar;45(3):361-2; author reply 363-4 [16332953.001]
  • [CommentIn] Rheumatology (Oxford). 2006 Mar;45(3):362-3; author reply 363-4 [16332952.001]
  • [CommentIn] Rheumatology (Oxford). 2006 Mar;45(3):361; author reply 363-4 [16332954.001]
  • (PMID = 15901903.001).
  • [ISSN] 1462-0324
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Jóhannsdóttir IM, Hjermstad MJ, Moum T, Wesenberg F, Hjorth L, Schrøder H, Lähteenmäki P, Jónmundsson G, Loge JH: Social outcomes in young adult survivors of low incidence childhood cancers. J Cancer Surviv; 2010 Jun;4(2):110-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study objective was to assess social outcomes in early adulthood after successful treatment for childhood acute myeloid leukemia (AML), Wilms tumor (WT) and infratentorial astrocytoma (IA).
  • METHODS: Nordic patients treated for AML, WT and IA from 1985 to 2001 identified from a database administered by NOPHO (Nordic Society of Paediatric Haematology and Oncology) were invited to participate in a postal survey.
  • [MeSH-major] Astrocytoma / psychology. Infratentorial Neoplasms / psychology. Leukemia, Myeloid, Acute / psychology. Social Behavior. Survivors / psychology. Wilms Tumor / psychology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):60-3 [10401499.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):104-10 [17554791.001]
  • [Cites] Curr Probl Cancer. 2003 May-Jun;27(3):112-26 [12748581.001]
  • [Cites] Psychooncology. 2003 Apr-May;12(3):213-25 [12673806.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] Int J Cancer Suppl. 1999;12:25-31 [10679867.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):417-23 [19479971.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1751-60 [16130127.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):807-14 [18989157.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):29-33 [10401494.001]
  • [Cites] Curr Probl Cancer. 2003 Jul-Aug;27(4):177-97 [12855950.001]
  • [Cites] Psychosomatics. 1997 Jan-Feb;38(1):54-62 [8997117.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4060-6 [11118467.001]
  • [Cites] J Cancer Surviv. 2008 Sep;2(3):205-14 [18663582.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3518-24 [17687156.001]
  • [Cites] J Cancer Surviv. 2008 Sep;2(3):149-58 [18792789.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2374-81 [19364956.001]
  • [Cites] Pediatr Hematol Oncol. 1997 Nov-Dec;14(6):513-24 [9383804.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Jan-Feb;16(1):9-21 [9932269.001]
  • [Cites] Med Pediatr Oncol. 1991;19(6):459-66 [1961132.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Acta Paediatr Scand. 1989 Sep;78(5):728-35 [2596279.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2390-5 [19224833.001]
  • [Cites] Pediatrics. 2007 Mar;119(3):554-68 [17332209.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):923-8 [15292930.001]
  • [Cites] Hum Reprod. 2008 Jan;23(1):178-86 [18024486.001]
  • [Cites] Lancet. 2000 Apr 15;355(9212):1310-4 [10776743.001]
  • [Cites] Lancet Oncol. 2008 Jun;9(6):569-76 [18510988.001]
  • [Cites] Pediatr Hematol Oncol. 1997 May-Jun;14(3):223-32 [9185207.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3392-9 [8490888.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):704-15 [16830322.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):1-11 [16718655.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):920-7 [17279494.001]
  • [Cites] Cancer. 1986 Jul 15;58(2 Suppl):529-33 [3719547.001]
  • [Cites] J Dev Behav Pediatr. 2007 Dec;28(6):448-55 [18091089.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1354-8 [8869099.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):229-34 [11838795.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jun;26(6):354-62 [15167348.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Nov-Dec;15(6):479-88 [9842641.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):251-73, xiii [18242324.001]
  • [Cites] Support Care Cancer. 2002 Nov;10(8):579-600 [12436217.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):61-70 [16572415.001]
  • [Cites] Psychooncology. 2002 Mar-Apr;11(2):132-41 [11921329.001]
  • [Cites] CA Cancer J Clin. 2004 Jul-Aug;54(4):208-36 [15253918.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):15-21 [15886508.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1523-7, discussion 1527-30 [11506960.001]
  • (PMID = 20082150.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Di Cataldo A, La Spina M, Bertuna G, Lo Nigro L, Branciforte F, Castagnola E: Spleen and lung involvement by Acinetobacter calcoaceticus bacteremia mimicking deep fungal infection in a child with acute non-lymphoblastic leukemia. Pediatr Blood Cancer; 2006 Feb;46(2):266
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen and lung involvement by Acinetobacter calcoaceticus bacteremia mimicking deep fungal infection in a child with acute non-lymphoblastic leukemia.
  • [MeSH-major] Acinetobacter Infections / drug therapy. Acinetobacter calcoaceticus. Anti-Infective Agents / administration & dosage. Ciprofloxacin / administration & dosage. Leukemia, Myeloid, Acute / complications


66. Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS: [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):706-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
  • OBJECTIVE: To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial.
  • METHODS: This trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from acute myelogenous leukemia ( AML except M3 type) , acute lymphocytic leukemia ( ALL) , chronic myelogenous leukemia-blast (CML-blast) , totally 155 patients.
  • In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin.
  • The acute myelogenous leukemia regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles.
  • The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
  • The incidence of non-hematological toxicities in domestic idarubicin group and imported idarubicin group was 84.
  • Discontinuation of treatment due to non-hematological toxicity was not neccessary.
  • CONCLUSION: Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia.
  • The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its non-hematological toxicity is tolerable.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274381.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


67. Nishizawa M, Hirayama F, Matsuyama N, Tada K, Kaneko H, Watanabe M, Miura Y, Tsudo M: [Transfusion-related acute lung injury with anti-leukocyte antibodies identified both in patient's serum and in red cell concentrate]. Rinsho Ketsueki; 2009 Jan;50(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transfusion-related acute lung injury with anti-leukocyte antibodies identified both in patient's serum and in red cell concentrate].
  • We report a fatal case of transfusion-related acute lung injury (TRALI) with anti-leukocyte antibodies detected both in the patient's serum and in the causative red cell concentrate (RC-M.A.P).
  • A 41-year-old Japanese woman diagnosed as having acute myeloid leukemia (AML, M2) developed TRALI caused by RC-M.A.P 15 days after the start of induction therapy for AML.
  • [MeSH-major] Acute Lung Injury / etiology. Autoantibodies / blood. Erythrocyte Transfusion / adverse effects. HLA Antigens / immunology. Leukemia, Myeloid, Acute / therapy. Leukocytes / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225224.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / HLA Antigens
  •  go-up   go-down


68. Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP: Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology; 2006 Oct;11(5):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis in acute leukemia: a clinico-hematological profile.
  • We studied 130 consecutive cases of acute leukemia over a 2-year period and identified 9 cases (6.9%) with active tuberculosis (TB).
  • Eight patients with TB had acute myeloid leukemia (AML).
  • Patients with AML were more likely to develop TB as compared to patients with acute lymphoblastic leukemia (ALL) despite the wider use of steroids and radiotherapy in ALL protocols {OR 4.41 (CI 0.53-36.44)}.
  • On the whole, TB did not cause any undue delay in chemotherapy and did not flare up during subsequent chemotherapy cycles.
  • However it is not a commonly described infection in acute leukemia and a high index of suspicion is warranted especially in areas endemic for TB.
  • [MeSH-major] Leukemia / complications. Tuberculosis / etiology
  • [MeSH-minor] Acute Disease. Adult. Antitubercular Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid. Male. Neutropenia. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607583.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


69. Kamel AM, El-Sharkawy N, Yassin D, Shaaban K, Hussein H, Sidhom I, Abo El-Naga S, Ameen M, El-Hattab O, Aly El-Din NH: P-gp expression and Rh 123 efflux assay have no impact on survival in Egyptian pediatric acute lymphoblastic leukemia patients. J Egypt Natl Canc Inst; 2005 Sep;17(3):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-gp expression and Rh 123 efflux assay have no impact on survival in Egyptian pediatric acute lymphoblastic leukemia patients.
  • PURPOSE: In a previous work we have studied MDR status in terms of P-glycoprotein (P-gp) expression and Rhodamine 123 efflux assay in Egyptian acute leukemia patients.
  • We have reported results comparable to the literature as regards ANLL both in pediatric and adult cases.
  • MATERIAL AND METHODS: A total of 108 cases were studied including 80 ALL and 28 ANLL.
  • ANLL cases included 18 male and 10 female with an age range of 6m to 18 yrs and a median of 8 yrs.
  • MDR expression and function were correlated to age, Hb, TLC, CD34 expression, immunophenotype and DNA index in ALL, FAB subtypes in ANLL as well as to CR, DFS and EFS in ALL.
  • In ANLL P-gp expression was encountered in 47.6% of cases, while positive Rh123 efflux assay was encountered in 75% of cases.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. P-Glycoprotein / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Rhodamine 123

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799654.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / P-Glycoprotein; 1N3CZ14C5O / Rhodamine 123
  •  go-up   go-down


70. Ustun C: Laparoscopic appendectomy in a patient with acute myelogenous leukemia with neutropenia. J Laparoendosc Adv Surg Tech A; 2007 Apr;17(2):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic appendectomy in a patient with acute myelogenous leukemia with neutropenia.
  • The management of acute myelogenous leukemia is often complicated by infections due to neutropenia, but the appendix is not a common site of infection in adult patients with acute myelogenous leukemia.
  • The diagnosis of acute appendicitis may be delayed or even missed because of the lack of characteristic signs and symptoms associated with acute appendicitis in neutropenic patients.
  • The case presented here is of a 33-year-old Hispanic man with acute myelogenous leukemia who developed severe diffuse acute abdominal pain with positive signs of rebound tenderness, fever, and hypotension ten days after receiving reinduction chemotherapy.
  • The patient was at his nadir, with a white blood cell count of 0.2 x 10(9)/L, platelet count of 20 x 10(9)/L, and hemoglobin of 7 g/dL.
  • A computed tomography scan of the abdomen was suspicious for acute appendicitis.
  • [MeSH-major] Appendicitis / surgery. Leukemia, Myeloid, Acute / complications

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Appendicitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484650.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Kern W, Haferlach T: [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]. Med Klin (Munich); 2005 Jan 15;100(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
  • Today, multiparameter flow cytometry allows the simultaneous assessment of up to five surface and cytoplasmic antigens in different cell populations from peripheral blood and bone marrow samples.
  • In the setting of diagnosing acute myeloid leukemias (AML) this method is used not only to subclassify AML and separate it from acute lymphoblastic and biphenotypic leukemias but also for the identification of leukemia-associated aberrant immunophenotypes (LAIPs).
  • Since these LAIPs are defined individually for each patient, leukemic bone marrow cells can be detected during the course of treatment using the LAIP allowing the quantification of minimal residual disease (MRD) which is not detectable by cytomorphology.
  • Due to its close correlation with the course of the disease and with the risk of relapse the MRD represents an important prognostic parameter which is increasingly used for stratification of therapy in clinical trials.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Myeloid, Acute / diagnosis. Neoplasm, Residual / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654545.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Epitopes; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


72. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, Wang S, Malek SN: Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood; 2010 Jul 8;116(1):71-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
  • The survival of most patients with acute myelogenous leukemia (AML) remains poor, and novel therapeutic approaches are needed to improve outcomes.
  • Given that the fraction of AML with mutated p53 is small ( approximately 10%), it appears rational to study MDM2 inhibitors as therapy for AML.
  • Here, we report results of a detailed characterization of sensitivity and resistance to treatment ex vivo with the MDM2 inhibitor MI219 in AML blasts from 109 patients.
  • In line with previous observations, all AML cases with mutated p53 were resistant to MI219.
  • Importantly, approximately 30% of AML cases with unmutated p53 also demonstrated primary resistance to MI219.
  • Analysis of potential mechanisms associated with MI219 resistance in AML blasts with wild-type p53 uncovered distinct molecular defects, including low or absent p53 protein induction after MDM2 inhibitor treatment or external irradiation.
  • Finally, analysis of very sensitive AML cases uncovered a strong and significant association with mutated Flt3 status (Flt3-ITD), which for the first time identified a clinically high-risk group of AML that may particularly benefit from MDM2 inhibitor treatment.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2006 Sep 6;25(17):4084-96 [16946709.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):702-12 [18719709.001]
  • [Cites] Nature. 2006 Nov 2;444(7115):61-6 [17080083.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):23-31 [17126603.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4777-85 [17699855.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • [Cites] Mol Cell. 2008 Feb 1;29(2):217-31 [18243116.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5318-24 [18765522.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1728-36 [18548093.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5303-14 [18521084.001]
  • [Cites] Mol Cell. 2008 Oct 24;32(2):180-9 [18951086.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):31-4 [19106616.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):171-83 [19249676.001]
  • [Cites] Leukemia. 2009 Apr;23(4):656-63 [19151774.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4300-8 [19190243.001]
  • [Cites] Cell. 2009 May 1;137(3):413-31 [19410540.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1711-9 [19411846.001]
  • [Cites] Cell. 2009 May 15;137(4):609-22 [19450511.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1647-8 [19448434.001]
  • [Cites] J Biol Chem. 2009 Sep 25;284(39):26315-21 [19648117.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):749-58 [19776744.001]
  • [Cites] Leukemia. 2010 Jan;24(1):33-43 [19946262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3099-104 [11867746.001]
  • [Cites] Cell. 2003 Mar 21;112(6):779-91 [12654245.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2233-8 [12952892.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1036-8 [14500851.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Nature. 2004 May 6;429(6987):86-92 [15103385.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Blood. 1991 Oct 1;78(7):1652-7 [1912553.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):534-40 [8249893.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Cell. 2005 Oct 7;123(1):49-63 [16213212.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3150-9 [16014563.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3609-17 [16081689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7 [16492744.001]
  • [Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]
  • [Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]
  • [Cites] J Cell Biol. 2006 May 22;173(4):533-44 [16717128.001]
  • [Cites] J Med Chem. 2006 Jun 15;49(12):3432-5 [16759082.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8 [18316739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10408-13 [18641120.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33030-5 [16905541.001]
  • (PMID = 20404136.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136537; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 1R01 CA136537-01; United States / NCRR NIH HHS / RR / UL1RR024986; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCRR NIH HHS / RR / UL1 RR024986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Indoles; 0 / MDM4 protein, human; 0 / MI-63 compound; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Spiro Compounds; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2904583
  •  go-up   go-down


73. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR: Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res; 2005 Mar 15;11(6):2320-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Overexpression of the multidrug resistance proteins P-glycoprotein (Pgp), multidrug resistance protein (MRP-1), breast cancer resistance protein (BCRP), and lung resistance protein (LRP) is associated with treatment failure in acute myeloid leukemia (AML) and other malignancies.
  • The Pgp modulator cyclosporin A has shown clinical efficacy in AML, whereas its analogue PSC-833 has not.
  • EXPERIMENTAL DESIGN: We studied the effects of cyclosporin A and PSC-833 on in vitro drug retention and cytotoxicity in resistant cell lines overexpressing Pgp, MRP-1, and BCRP and on nuclear-cytoplasmic drug distribution and cytotoxicity in cells overexpressing LRP.
  • Moreover, cyclosporin A enhanced nuclear distribution of doxorubicin in 8226/MR20 cells, which also express LRP, and increased doxorubicin cytotoxicity 12-fold without an effect on cellular doxorubicin content, consistent with expression of wild-type BCRP, which does not efflux doxorubicin.
  • Cyclosporin A also enhanced nuclear doxorubicin distribution in a second cell line with LRP overexpression, HT1080/DR4.
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Antibiotics, Antineoplastic / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Nucleus / metabolism. Cells, Cultured. Cytoplasm / metabolism. Doxorubicin / metabolism. HL-60 Cells / drug effects. HL-60 Cells / metabolism. Humans. Kidney / drug effects. Kidney / metabolism. Mitoxantrone / metabolism. Neoplasm Proteins / metabolism. Vault Ribonucleoprotein Particles / metabolism

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858153 for PMID:15788683 [PharmGKB] .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788683.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 16056; United States / NCI NIH HHS / CA / R21 CA 98457; United States / NCI NIH HHS / CA / T32 CA 09072-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antibiotics, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


74. Miron I, Mihăilă D, Aprodu G, Miron L, Plămădeală P, Moisă SM: Immunoproliferative small intestinal disease versus colonic monoblastic sarcoma in a 2-year-old boy. Rom J Morphol Embryol; 2009;50(4):733-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease versus colonic monoblastic sarcoma in a 2-year-old boy.
  • The authors present a case of colonic monoblastic sarcoma, previously treated for other digestive abnormalities (malabsorbtion, Hirschprung's disease).
  • Important similitudes with immunoproliferative small intestinal disease (IPSID) lymphoma were demonstrated for this patient (male, 2-year-old).
  • Some particularities of this case are the young age and the extremely rapid development of the malignant disease in a patient with no previous signs of acute non-lymphoblastic leukemia.
  • The initial diagnosis was of malabsorbtion syndrome, based on the clinical exam at presentation, and then the patient was thought to have a form of Hirschprung's disease, due to a functional intestinal disorder (slow transit).
  • After the necropsy, pathologists diagnosed an immunoproliferative small intestinal disease, and four years later, they performed a more appropriate pathological exam, which explained better clinical symptoms associated to this complex case.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Immunoproliferative Small Intestinal Disease / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Hirschsprung Disease / diagnosis. Humans. Malabsorption Syndromes / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942975.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


75. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N: Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer; 2008 Oct 1;113(7):1596-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
  • Many patients will either not respond or will have only limited and/or brief responses to single-agent therapy.
  • Eventually, 30% of patients with MDS will progress and develop acute myeloid leukemia (AML).
  • METHODS: 5-Azacytidine (AZA) and thalidomide were administered to 40 patients with MDS or AML.
  • AZA was given at a dose of 75 mg/m2 subcutaneously for 5 of 28 days together with thalidomide starting at a dose of 50 mg per day and increasing to 100 mg per.
  • Six patients had refractory anemia (RA), 2 patients had RA with ringed sideroblasts, 10 patients had RA with excess blasts (RAEB), 1 patient had RAEB in transformation, 4 patients had chronic myelomonocytic leukemia, 1 patient had chronic idiopathic myelofibrosis, and 16 patients had AML.
  • RESULTS: A hematologic improvement (HI) was observed in 15 of 36 patients (42%), stable disease was observed in 5 of 36 patients (14%), and 10 of 36 patients (28%) had disease progression.
  • It was noteworthy that 9 of 14 patients with AML had a history of prior MDS, 2 of 9 patients achieved a CR, 4 of 9 patients had HI (HI-E and bilineage HI), and 1 patient had stable disease and was continuing treatment.
  • CONCLUSIONS: The current findings indicated that a combination of low-dose AZA and thalidomide was well tolerated and was effective therapy for the treatment of patients with MDS and AML arising from prior MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Azacitidine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Thalidomide / administration & dosage


76. Bae SY, Kim JS, Ryeu BJ, Lee KN, Lee CK, Kim YK, Lim CS, Cho Y, Choi CW, Ryu SW, Yoon SY: Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases. Cancer Genet Cytogenet; 2010 May;199(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases.
  • Variants of the t(8;21)(q22;q22) involving chromosome 8, 21, and other chromosomes account for approximately 3% of all t(8;21)(q22;q22) found in patients with acute myeloid leukemia (AML).
  • The clinicopathologic features of AML with the variant t(8;21) have not been well established.
  • We report three cases of AML with variants of t(8;21) characterized, respectively, by derivative 8 with the interstitial inverted insertion of 21q and concurrent monosomy 21, t(8;18;21)(p22;q11.3;q22), and t(2;21;8)(q11.2;q22;q22).
  • Among these cases, three-way breakpoints 18p11.3 and 2q11.2 have not been previously reported.
  • [MeSH-major] Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic


77. Tessema M, Länger F, Bock O, Seltsam A, Metzig K, Hasemeier B, Kreipe H, Lehmann U: Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. Int J Oncol; 2005 Feb;26(2):499-507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to elucidate the contribution of H19 and IGF-2 to leukemogenesis, the mRNA expression level of both genes were quantitated in bone marrow biopsies and peripheral blood samples from normal (n=98), chronic myelomonocytic leukemia (CMML, n=43), chronic myelogenous leukemia (CML, n=40) and, acute myelogenous leukemia (AML, n=32) cases.
  • This down-regulation was not accompanied by changes in methylation of the differentially methylated region (DMR).
  • No correlations between imprinting status (mono- versus biallelic expression), quantitative mRNA expression levels and course of disease were found for the IGF-2 gene.
  • The data suggest a disturbed regulation of the IGF-2/H19 locus in myeloid leukemias which is not caused by loss of imprinting.
  • [MeSH-minor] Alleles. Biopsy. Bone Marrow Cells / metabolism. DNA Methylation. DNA, Complementary / metabolism. Genotype. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myelomonocytic, Chronic / genetics. Models, Genetic. RNA, Long Noncoding. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15645136.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / H19 long non-coding RNA; 0 / RNA, Long Noncoding; 0 / RNA, Messenger; 0 / RNA, Untranslated; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


78. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C: Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle; 2008 Apr 15;7(8):1047-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features.
  • The metalloprotease 9 (MMP-9), a known mediator of tumour invasion, is secreted as a 92 kDa pro-form but a non-secreted variant of 85 Kda has been described.
  • We previously showed that the DNA repair protein Ku interacts at the cell surface of leukaemia cell lines with the 85 Kda pro-form of MMP-9 and these Ku/MMP-9 complexes regulates cell invasion, highlighting their importance in haematological malignancies.
  • We demonstrate here that all samples of acute myeloid leukaemia (AML) blasts purified from bone marrow of 16 affected patients express the 85 Kda form of MMP-9.
  • However, only AML that display monocytic lineage markers (AML4/5) express this form at the cell surface with co-expression of the membrane associated form of Ku.
  • Blocking antibodies directed against Ku or MMP-9 specifically inhibited cell invasion of those expressing Ku/MMP-9 on the cell surface.
  • The membrane form of Ku might represent an important factor in the exposition to the cell surface of this specific MMP-9 pro-form in AML with monocytic features.
  • These results might have important functional significance in the occurrence of extra-medullar infiltrates of leukaemia cells that occurs frequently during the onset of monocyte-related AML sub-types.
  • [MeSH-major] DNA Helicases / metabolism. Leukemia, Myeloid, Acute / metabolism. Matrix Metalloproteinase 9 / metabolism. Membrane Proteins / metabolism. Monocytes / metabolism. Neoplasm Invasiveness / physiopathology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414048.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / XRCC5 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.4.- / DNA Helicases
  •  go-up   go-down


79. Zhang Y, He Q, Huang XJ, Jiang H, Yang SM, Lu J, Qing YZ, Shi Y, Dang H, Qiu JY, Lu DP: [Cytogenetic study on eosinophilia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun;15(3):454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of study was to investigate the importance of chromosome aberration in differential diagnosis of eosinophilia and the chromosomal aberrations involved in patients with clonal eosinophilia.
  • Combining clinical, hematological and cytogenetical data, the 5 patients were diagnosed as acute myeloid leukemia with eosinophilia, chronic eosinophilic leukemia, 8p11 myeloproliferative syndrome, chronic myeloid leukemia in acute phase and acute myeloid leukemia-M(4Eo) respectively.
  • In conclusion, cytogenetical detection is very important in differential diagnosis of clonal eosinophilic disorders and chronic eosinophilic leukemia, which is suggested to be done routinely in clinic.

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605843.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics; 2005 Feb 1;21(3):379-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AVAILABILITY: The HCV website can be accessed via http://hcv.lanl.gov and http://hcv-db.org.

  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377502.001).
  • [ISSN] 1367-4803
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Grant] United States / PHS HHS / / 04-2085
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


81. Kang LC, Dunphy CH: Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med; 2006 Feb;130(2):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
  • CONTEXT: MIC2 ("thymus leukemia") antigen has been shown to be expressed by T cells and monocytes, as well as B cells and granulocyte-lineage cells.
  • It is most intensely expressed by the most immature thymus T-lineage cells and is more intensely expressed by CD34-positive/CD33-positive myeloid cells (compared to more mature myeloid cells) and the earliest CD34-positive/CD10-positive B-cell precursor cells (compared to cells of later B-cell precursor stages).
  • CD99 (MIC2) is characteristically expressed in precursor B- and T-cell lymphoblastic lymphomas/leukemias, as well as in Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET).
  • It has also been shown to be expressed in a few terminal deoxynucleotidyl transferase (TdT)-positive myeloid processes, but has been uniformly negative in TdT-negative myeloid processes.
  • A more recent study showed that 43% of acute myeloid leukemias (AMLs) and 55% of chloromas express CD99, concluding that CD99 is commonly expressed in AML and rarely seen in myeloproliferative disorders, myelodysplastic syndromes, or normal bone marrow.
  • Although this study speculated that MIC2 expression was probably not limited to TdT-positive AML, there was no comparison with TdT reactivity in this study.
  • OBJECTIVE: Since AML and high-grade myelodysplastic syndrome may occasionally be difficult to distinguish morphologically from acute lymphoblastic leukemia and ES/ PNET, we undertook a study to analyze MIC2 expression in conjunction with TdT reactivity in distinguishing AML or high-grade myelodysplastic syndrome from acute lymphoblastic leukemia and ES/PNET.
  • DESIGN: We studied bone marrow core and clot paraffin specimens from AML (classified according to criteria of the World Health Organization; n = 49), myelodysplastic syndromes (n = 4), precursor B-cell acute lymphoblastic leukemia (n = 4), ES/PNET (n = 1), and normal bone marrow (n = 3) with MIC2 (CD99) and TdT immunohistochemistry.
  • RESULTS: Overall, CD99 was expressed in 24 (49%) of 49 AML cases, including all (11/11) TdT-positive cases.
  • CD99 was expressed in all subtypes of AML except M5.
  • Expression of TdT was limited to a subset of AML-M0, -M1, -M2, and -M4, and AML with multilineage dysplasia.
  • CONCLUSIONS: In contrast to a previous study, CD99 expression was not restricted to TdT-positive hematologic proliferations.
  • In particular, the CD99-positive M3 and M7 AMLs were TdT negative.
  • An M5 AML may likely be excluded based on a uniform TdT-negative/CD99-negative immunophenotype.
  • [MeSH-major] Antigens, CD / metabolism. Bone Marrow / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism
  • [MeSH-minor] Diagnosis, Differential. Flow Cytometry. Humans. Immunohistochemistry. Neuroectodermal Tumors, Primitive / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retrospective Studies. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454553.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


82. Yoneda K, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, Yagi H, Narita N, Kimura H: The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res; 2005 Feb;29(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy.
  • In this study, we assessed the Valpha24+ NKT cell numbers in peripheral blood (PB) from 30 healthy donors and 70 patients with haematopoietic malignancy including chronic myelogenous leukemia (CML), malignant lymphoma (ML), acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
  • Here, we demonstrated that PB Valpha24+ NKT cell numbers were significantly decreased in all the patients with haematopoietic malignancy in comparison with that in healthy donors (P < 0.005).
  • In particular CD4- CD8- Valpha24+ NKT cell numbers were more significantly decreased in the patients with haematopoietic malignancy (P < 0.0001).
  • [MeSH-major] Hematologic Neoplasms / blood. Killer Cells, Natural / cytology. Receptors, Antigen, T-Cell, alpha-beta / biosynthesis
  • [MeSH-minor] Antigens, CD4 / biosynthesis. Antigens, CD8 / biosynthesis. Flow Cytometry. Humans. Lymphocyte Count. Lymphocytes / cytology. Lymphocytes / immunology. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607362.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


83. Müller AM, Duque J, Shizuru JA, Lübbert M: Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene; 2008 Oct 2;27(44):5759-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.
  • A great proportion of acute myeloid leukemias (AMLs) display cytogenetic abnormalities including chromosomal aberrations and/or submicroscopic mutations.
  • These abnormalities significantly influence the prognosis of the disease.
  • Core binding factor (CBF) leukemias denote AMLs with chromosomal aberrations disrupting one of the CBF transcription factor genes; the most common examples are translocation t(8;21) and inversion inv(16), which result in the generation of the AML1-ETO and CBFbeta-MYH11 fusion proteins, respectively.
  • However, in murine models, these alterations alone do not suffice to generate full-blown leukemia, but rather, complementary events are required.
  • In fact, a substantial proportion of primary CBF leukemias display additional activating mutations, mostly of the receptor tyrosine kinase (RTK) c-KIT.
  • Here, we present a concise review on complementing mutations in CBF leukemias including pathophysiology, mouse models, and clinical implications.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factors / genetics. Leukemia, Myeloid, Acute / diagnosis. Mutation. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Genetic Complementation Test. Mice. Prognosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604246.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 118
  •  go-up   go-down


84. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res; 2010 Jul;34(7):877-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
  • In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features.
  • Median OS and DFS are not reached (67% alive 12.5-31 months, 58% in CR 11.4-30 months), with median follow-up 22 months.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • [Cites] Cell Death Differ. 2001 Jul;8(7):715-24 [11464216.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]
  • [Cites] Genome Biol. 2001;2(10):RESEARCH0041 [11597333.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3527-38 [12429644.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):307-15 [12538483.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1822-33 [12702569.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Am J Med. 1969 Sep;47(3):351-66 [5258033.001]
  • [Cites] Ann Intern Med. 1975 Jan;82(1):54-7 [16553.001]
  • [Cites] Medicine (Baltimore). 1980 Nov;59(6):409-25 [7003298.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4856-61 [8895733.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):138-48 [16432172.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):697-706 [16690529.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1810-6 [17095617.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73 [17671131.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4052-62 [19144991.001]
  • [CommentIn] Leuk Res. 2010 Jul;34(7):856-7 [20378170.001]
  • (PMID = 19962759.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ NIHMS158765; NLM/ PMC2875369
  •  go-up   go-down


85. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I, Japanese Childhood AML Cooperative Study Group: Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol; 2007 Dec 1;25(34):5442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
  • PURPOSE: To evaluate a less intensive chemotherapeutic regimen specifically designed for patients with Down syndrome (DS) and acute myeloid leukemia (AML), and to determine the prognostic factors for event-free survival.
  • PATIENTS AND METHODS: Seventy-two patients with AML-DS were treated with remission induction chemotherapy consisting of pirarubicin (25 mg/m2/d for 2 days), cytarabine (100 mg/m2/d for 7 days), and etoposide (150 mg/m2/d for 3 days).
  • Prophylaxis for CNS leukemia was not included.
  • RESULTS: All but two patients were younger than 4 years, and 67 of the 72 patients (93%) were diagnosed as acute megakaryoblastic leukemia (AMKL).
  • CONCLUSION: A less intensive chemotherapeutic regimen produces excellent outcomes in standard-risk AML-DS patient.
  • Risk-oriented therapy should be considered for future trials in AML-DS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Down Syndrome / complications. Leukemia, Megakaryoblastic, Acute / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Infant. Male. Prospective Studies. Treatment Outcome


86. Slovak ML, Smith DD, Bedell V, Hsu YH, O'Donnell M, Forman SJ, Gaal K, McDaniel L, Schultz R, Ballif BC, Shaffer LG: Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol Cytogenet; 2010;3:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We performed an exploratory study on 30 cases of MDS, myeloproliferative neoplasia (MPN) or evolving acute myeloid leukemia (AML) (% bone marrow blasts ≤ 30%, range 0-30%, median, 8%) by aCGH, using a genome-wide bacterial artificial chromosome (BAC) microarray.
  • Cryptic 344-kb RUNX1 deletions were found in three patients at time of AML transformation.
  • CONCLUSIONS: The detection of previously known and unknown genomic alterations suggests that aCGH has considerable promise for identification of both recurring microscopic and submicroscopic genomic imbalances that contribute to myeloid disease pathogenesis and progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21078186.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3000833
  •  go-up   go-down


87. Fuchs O: Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol; 2010 Nov;3(3):98-122
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear factor-kappaB (NF-κB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis.
  • NF-κB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), lymphomas and in multiple myeloma (MM).
  • Triptolide (diterpenoid triepoxyde), a purified component of a traditional Chinese medicine, extracted from a shrub-like vine named Trypterygium wilfordii Hook F (TWHF) inhibits transcriptional activation of NF-κB and downregulates the expression of various NF-κB-regulated genes.
  • Triptolide (10-80 ng/ml) induces apoptosis of MM cells and effectively inhibits cell growth of MM cells.
  • LC-1, the dimethylamino-parthenolide (DMAPT) derivative demonstrated significant cytotoxicity to AML blasts targeting NF-κB.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594187.001).
  • [ISSN] 1874-4702
  • [Journal-full-title] Current molecular pharmacology
  • [ISO-abbreviation] Curr Mol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Epoxy Compounds; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Phenanthrenes; 0 / Proteasome Inhibitors; 139874-52-5 / NF-kappaB inhibitor alpha; 19ALD1S53J / triptolide; 2M36281008 / Etodolac; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


88. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, Bunce CM: The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res; 2009 Mar 9;662(1-2):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
  • Other studies have demonstrated the oxidative activation of polycyclic aromatic hydrocarbon (PAH) procarcinogens by AKR1C3 in cell-free systems.
  • Quantitative RT-PCR identified AKR1C3 as the predominant AKR1C isoform expressed in acute myeloid leukemia (AML).
  • Exposure of K562 and KG1a myeloid cell lines to the known AKR1C3 substrate 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol (7,12-DMBA-3,4-diol) resulted in both single strand DNA breaks and oxidative DNA damage as measured using conventional and FPG-modified comet assays respectively.
  • Knockdown of AKR1C3 did not alter single strand DNA breaks following 7,12-DMBA-3,4-diol exposure but significantly decreased oxidative DNA damage.
  • A similar interrelationship between AKR1C3 activity and 7,12-DMBA-3,4-diol mediated oxidative DNA damage but not single strand breaks was observed in KG1a cells.
  • Since K562 cells are a model of AML blast crisis of chronic myeloid leukemia (CML) the data presented here identify AKR1C3 as a novel mediator of carcinogen-induced initiation of leukemia, as a novel regulator of erythroid differentiation and paradoxically as a potential new target in the treatment of CML.
  • [MeSH-major] 3-Hydroxysteroid Dehydrogenases / metabolism. 9,10-Dimethyl-1,2-benzanthracene / analogs & derivatives. DNA Damage. Hydroxyprostaglandin Dehydrogenases / metabolism. Leukemia, Myeloid, Acute / enzymology. Oxidative Stress
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Gene Expression Regulation, Leukemic. Gene Knockdown Techniques. Glycophorin / metabolism. Hemoglobins / metabolism. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162045.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glycophorin; 0 / Hemoglobins; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 72617-60-8 / 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases
  •  go-up   go-down


89. Tohyama K, Shiga S, Itose Y, Uchihashi K, Ohkura M, Takahashi K, Itoh M, Ichiyama S, Hamaguchi Y: Improved detection of minimal acute myeloid leukemia cells by the use of the combined parameters of XE-2100 hematology analyzer. Cytometry B Clin Cytom; 2005 Jul;66(1):18-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved detection of minimal acute myeloid leukemia cells by the use of the combined parameters of XE-2100 hematology analyzer.
  • BACKGROUND: For the diagnosis and therapy of acute leukemia, it is important to detect a small number of leukemic cells precisely.
  • Although several automated hematology analyzers that carry blast-detecting programs have been developed, they do not exert sufficient detection sensitivity to exceed the sensitivity of manual eye counting method.
  • A small number of leukemic myeloblasts was detected at the better sensitivity than the eye counting method in the clinical course of the patients with acute myeloid leukemia.
  • CONCLUSIONS: The daily practical use of this blast multi-scoring program will surely contribute to sensitive, objective, and real-time evaluation of the control of acute myeloid leukemia with a low cost.
  • [MeSH-major] Hematologic Tests / methods. Hematology / methods. Leukemia, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Erythrocyte Count / instrumentation. Erythrocyte Count / methods. Female. Humans. Leukocyte Count / instrumentation. Leukocyte Count / methods. Male. Middle Aged. Platelet Count / instrumentation. Platelet Count / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15800879.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Fatih T, Selim Y, Mesut A, Demirel YN, Yuksel P: An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia. Intern Med; 2007;46(6):325-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia.
  • Examination of the pleural fluid revealed myeloid blasts.
  • Bone marrow aspiration smear and flow cytometric analysis of the bone marrow and pleural fluid were consistent with acute myeloid leukemia.
  • [MeSH-major] Aortic Valve Stenosis / complications. Leukemia, Myeloid / complications. Pleural Effusion / etiology
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Fatal Outcome. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Liver Diseases / complications. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Mycoses / complications. Mycoses / diagnosis. Mycoses / therapy. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380003.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; FLAG protocol
  •  go-up   go-down


91. Bayona C, Lassaletta A, Pérez A, Sevilla J, Albi G, Villa JR, Madero L: [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia]. An Pediatr (Barc); 2007 Sep;67(3):278-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia].
  • [Transliterated title] Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblástica aguda.
  • [MeSH-major] Aspergillosis / complications. Hemoptysis / etiology. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785168.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


92. Suzukawa K, Shimizu S, Nemoto N, Takei N, Taki T, Nagasawa T: Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21). Int J Hematol; 2005 Jul;82(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21).
  • More than 40 genes have been reported as translocation partners of the mixed lineage leukemia gene (MLL) in hematologic malignancies.
  • On the other hand, there is only 1 report of an MLL-AF17 fusion transcript in acute myeloid leukemia (AML).
  • Here we describe a 40-year-old man with a diagnosis of AML involving t(11;17)(q23;q21).
  • Although the previously reported form of the MLL-AF17 fusion transcript was not detected by reverse transcriptase-polymerase chain reaction (PCR) analysis, a novel form of an MLL-AF17 fusion transcript joining MLL exon 6 to AF17 exon 9 was detected by complementary DNA panhandle PCR.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Leukemia, Monocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / genetics. Chromosome Breakage. Histone-Lysine N-Methyltransferase. Humans. Leucine Zippers. Male. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14 ):4075-80 [12124344.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):333-7 [11809673.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):54-9 [12885463.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4261-5 [10485469.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8107-11 [8058765.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Cancer Genet Cytogenet. 1994 May;74(1):50-3 [8194047.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9597-602 [10920186.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):178-9 [14734237.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):33-7 [11782354.001]
  • (PMID = 16105757.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / MLL-AF17 fusion protein, human; 0 / MLLT6 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


93. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ: Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer; 2007 Mar 15;109(6):1152-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
  • BACKGROUND: CXC chemokine receptor 4 (CXCR4) expression in acute myeloid leukemia (AML) is reported to correlate with FLT3 gene mutation and poorer prognosis.
  • The prognostic significance of CXCR4 expression in patients with AML that have a normal karyotype and no evidence of FLT3 gene mutations was examined.
  • METHODS: The prognostic significance of CXCR4 expression in 122 AML patients with normal karyotype and no evidence of FLT3 gene mutation treated at our institution between 1997 and 2003 was analyzed.
  • Sixty-six patients died, including 9 with no evidence of disease.
  • CONCLUSIONS.: The results suggest that CXCR4 expression is associated with poor prognosis in AML patients with an unmutated FLT3 gene.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Receptors, CXCR4 / analysis. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Karyotyping. Male. Middle Aged. Mutation. Prognosis. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315232.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


94. Chen HC, Hu WX, Liu QX, Li WK, Chen FZ, Rao ZZ, Liu XF, Luo YP, Cao YF: Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev; 2008 Jun;17(3):251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
  • The genetic polymorphisms of biotransformation phase I enzymes, cytochrome P450 (CYP1A1 and CYP2D6), and phase II enzymes, glutathione S-transferase (GSTM1 and GSTT1), were analyzed in 204 healthy persons and 348 leukemia patients, who suffered from also acute lymphoblastic leukemia (ALL), acute nonlymphoblastic leukemia (ANLL) chronic myelogenous leukemia (CML), from the Han ethnic group in Changsha City of Hunan Province of China.
  • Our results showed that the frequencies of polymorphisms of CYP1A1, CYP2D6 and GSTT1 among the groups including acute lymphoblastic leukemia, ANLL, chronic myelogenous leukemia and healthy control have no significant differences.
  • The variation of GSTM1-null genotype alone correlated with the development of ANLL.
  • The combined genotypes of GSTM1-null with GSTT1-null, or GSTM1-null with CYP1A1 heterozygous mutant, or GSTM1-null with CYP1A1 heterozygous mutant and CYP2D6 heterozygous mutant, or GSTM1-null with CYP1A1 heterozygous mutant, CYP2D6 heterozygous mutant and GSTT1-null were found in individuals with high risk of ANLL.
  • All these findings suggest that GSTM1-null genotype alone or in coordination with the relevant genotypes of other metabolic enzymes might be susceptibility factors in the etiology of ANLL.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP2D6 / genetics. Glutathione Transferase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Case-Control Studies. DNA Mutational Analysis. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414197.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


95. Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA. Best Pract Res Clin Haematol; 2008 Mar;21(1):1-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561374.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] England
  •  go-up   go-down


96. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A: Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia; 2008 Jul;22(7):1449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
  • [MeSH-major] Apoptosis / drug effects. Benzamides / pharmacology. Benzimidazoles / pharmacology. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Histone Deacetylase Inhibitors. Histones / metabolism. Leukemia, Myeloid, Acute / drug therapy. MAP Kinase Signaling System / drug effects. Promoter Regions, Genetic. Pyridines / pharmacology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185526.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AZD 6244; 0 / Benzamides; 0 / Benzimidazoles; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Pyridines; 1ZNY4FKK9H / entinostat; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


97. Shali W, Hélias C, Fohrer C, Struski S, Gervais C, Falkenrodt A, Leymarie V, Lioure B, Raby P, Herbrecht R, Lessard M: Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet; 2006 Jul 15;168(2):133-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH.
  • We report a series of 43 consecutive therapy-related myelodysplastic syndromes (t-MDS) or acute myeloid leukemias (t-AML) observed for 6 years.
  • These cases were classified into three groups according to the primary diagnosis.
  • Conventional cytogenetic and fluorescent in situ hybridization (FISH)/ multiplex FISH (M-FISH) methods were used to analyze cytogenetic characteristics of secondary MDS/AML.
  • A considerable proportion of recurrent balanced translocations characterized t-AML secondary to therapy.
  • After treatment for lymphomas and chronic myeloproliferative diseases, there were more complex unbalanced abnormalities than the control group.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics


98. McComb T, Sudesh V, Richardson M: Volume Bragg grating stabilized spectrally narrow Tm fiber laser. Opt Lett; 2008 Apr 15;33(8):881-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Tm-doped large mode area (LMA) silica fiber laser has been locked to a stable wavelength of 2,053.9 nm using a volume Bragg grating (VBG).
  • Although this laser had modest output (approximately 5W) and slope efficiency (41%), this new approach to spectrally limiting the output of LMA fiber lasers is inherently extendable to kilowatt powers, opening up several applications including high-power pulsed fiber lasers and spectral beam combining.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414564.001).
  • [ISSN] 0146-9592
  • [Journal-full-title] Optics letters
  • [ISO-abbreviation] Opt Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Jenkins C, Hewamana S, Gilkes A, Neelakantan S, Crooks P, Mills K, Pepper C, Burnett A: Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol; 2008 Dec;143(5):661-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
  • Nuclear factor-kappaB (NF-kappaB) has been implicated in a number of malignancies and has been suggested to be a potential molecular target in the treatment of leukaemia.
  • This study demonstrated the constitutive activation of NF-kappaB in human myeloid blasts and a clear correlation between NF-kappaB expression and in vitro cytoprotection.
  • High NF-kappaB expression was found in many of the poor prognostic acute myeloid leukaemia (AML) subtypes, such as French-American-British classification M0 and M7, and the poor cytogenetic risk group.
  • The in vitro effects of LC-1, a novel dimethylamino-parthenolide analogue, were assessed in 62 primary untreated AML samples.
  • LC-1 was found to be cytotoxic to AML cells in a dose-dependent manner, mediated through the induction of apoptosis.
  • The median drug concentration necessary to kill 50% of the cells was 4.5 micromol/l for AML cells, compared with 12.8 micromol/l for normal marrow cells.
  • Consequently, LC-1 treatment provides a proof of principle for the use of NF-kappaB inhibitors in the treatment of AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. NF-kappa B / antagonists & inhibitors. Sesquiterpenes / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036014.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / LC-1 compound; 0 / NF-kappa B; 0 / Sesquiterpenes
  •  go-up   go-down


100. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon MC, Sinclair GD, Leber B, Johnson PR, Macheta A, Yin JA, Barnett MJ, Lister TA, Fitzgibbon J: Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood; 2008 Dec 1;112(12):4639-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.
  • Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML).
  • The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported.
  • We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1.
  • Germ- line RUNX1 mutations were identified in 5 pedigrees with a 3:2 predominance of N-terminal mutations.
  • Several affected members had normal platelet counts or platelet function, features not previously reported in FPD/AML.
  • The median incidence of MDS/AML among carriers of RUNX1 mutation was 35%.
  • Individual treatments varied but included hematopoietic stem cell transplantation from siblings before recognition of the inherited leukemogenic mutation.
  • Transplantation was associated with a high incidence of complications including early relapse, failure of engraftment, and posttransplantation lymphoproliferative disorder.
  • Given the small size of modern families and the clinical heterogeneity of this syndrome, the diagnosis of FPD/AML could be easily overlooked and may be more prevalent than previously recognized.
  • Therefore, it would appear prudent to screen young patients with MDS/AML for RUNX1 mutation, before consideration of sibling hematopoietic stem cell transplantation.
  • [MeSH-major] Blood Platelet Disorders / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid / genetics. Pedigree
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Disease Progression. Family. Female. Hematopoietic Stem Cell Transplantation / contraindications. Humans. Male. Middle Aged. Mutation / physiology. Young Adult






Advertisement